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ABSTRACT 
Letha M. Joseph: Management of Comorbid Depression in Veterans with Diabetes 
(Under the direction of Diane Berry) 
Objective: Patients with diabetes have an increased risk of developing depression.  Comorbid 
depression in patients with diabetes affects their health-related quality of life, diabetes self-
management, and health care utilization.  The purpose of this study was to examine the 
feasibility of screening for depression in patients with diabetes while they were hospitalized for 
medical illness. 
Methods: The electronic health records of 193 patients admitted to medical units at a local 
facility from July 2016 to December 2016 were assessed for the presence of diabetes.  Twenty-
one patients with type 2 diabetes and with glycated hemoglobin above 7% were consented and 
screened for depression using the Patient Health Questionnaire (PHQ-2).  Seven patients with 
positive symptoms for depression were enrolled in the study.  The researcher alerted the medical 
provider via the electronic medical record about the patients with depression symptoms and the 
provider discussed options for management of depression with the patient and initiated 
treatment.  The patients answered the PHQ-9, the Veterans RAND-12 and the Stanford Diabetes 
Questionnaire at baseline and at eight weeks and 12 weeks after discharge from the hospital.  
Five patients completed the study.  At the completion of the study, the hospitalist team providers 
and the patients answered survey questions about the process.  
Results: The process of screening for depression at admission, notifying the provider by way of 
electronic medical record that the patient screened positive for depression with suggestions for 
medication and psychiatric counseling was feasible and acceptable to providers. Patients also felt 
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the program was acceptable and helped them get the assistance they needed for depression. 
Statistics are not reported due to the small sample size.  
Conclusion: The results suggest that screening for depressive symptoms while admitted with 
medical illness was feasible and acceptable to patients and providers. A randomized controlled 
pilot study will be conducted next to establish efficacy.  
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CHAPTER 1: INTRODUCTION 
Background and Significance 
According to the Centers for Disease Control and Prevention (CDC), more than 29 million 
people in the United States (U.S.) suffer from diabetes (CDC, 2014).  The incidence of depression in 
patients with diabetes is higher than the incidence of depression in patients without diabetes (Hasan, 
Mamun, Clavarino, & Kairuz, 2015).  The presence of diabetes almost doubles the odds of 
developing depression (Hsu et al., 2012; Vamos, Mucsi, Keszei, Kopp, & Novak, 2009).  Depressive 
symptoms in adults with diabetes negatively affect their self-management and adherence to diabetes 
treatment, which lead to poor glycemic control, and microvascular and macrovascular complications 
(Egede & Ellis, 2008; Ford, 2008; Gonzalez et al., 2007; Katon et al., 2008).  Poor clinical outcomes 
in diabetes care in patients with depression is well documented in the literature (Shah, Mezzio, Ho, & 
Ip, 2015; Waitzfelder et al., 2010).  According to the Reasons for Geographic and Racial Differences 
in Stroke (REGARDS) study, comorbid stress and depression are common among patients with 
diabetes and are associated with poor cardiovascular outcomes (Cummings et al., 2016).  Singh and 
colleagues (2015) also identified a strong association between depression and the progression of 
diabetes to cardiovascular disease.  Patients with diabetes and comorbid depression have a two-fold 
higher risk of having a myocardial infarction compared with patients who have either diabetes or 
depression alone (Scherrer et al., 2011).  Zhang and colleagues (2005) argued that comorbid 
depression in patients with diabetes was associated with increased mortality, whereas depression did 
not increase mortality in patients without diabetes.  Van Dooren and colleagues (2013) reported that 
depression is associated with nearly 1.5-fold increased risk for mortality in patients with diabetes.  
Bogner and colleagues (2007) reported a reduction in five-year all-cause mortality in older adults 
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with diabetes when they received appropriate management of their comorbid depression.  Gonzalez 
et al. (2007) noticed that even minor depression could affect diabetes self-management.  However, Li 
et al. (2009) reported that nearly 45% of patients with diabetes suffer from undiagnosed depression.  
Routine screening and management of depressive symptoms may improve diabetes care 
outcomes.  The American Diabetes Association’s (ADA) Foundation of diabetes self-management 
includes routine depression screening and management of depressive symptoms using a stepwise 
collaborative care approach (ADA, 2016).  Patients with co-morbid depression report more diabetes-
related symptoms and utilize health care services more frequently than patients with diabetes who do 
not have any depressive symptoms (Molosankwe, Patel, Gagliardino, Knapp, & McDaid, 2012).  
Vamos et al., (2009) reported more frequent and prolonged hospitalizations and extended illnesses 
for patients with diabetes and comorbid depression compared with patients with diabetes alone.  The 
Agency for Healthcare Research and Quality's Healthcare Cost and Utilization Project reported 30-
day all-cause readmission rates of 20.3% among patients with diabetes and related complications 
(Elixhauser & Steiner, 2013).  Unidentified or poorly managed depression may be contributing to 
this high utilization of health care services.  The ADA (2016) identifies hospitalization as a potential 
opportunity for depression screening and initiating collaborative depression management as part of 
comprehensive diabetes care. 
Problem Statement  
Unidentified depression exists in patients with diabetes.  Comorbid depression affects 
diabetes self-management and leads to poor diabetes outcomes and high utilization of healthcare 
services.  Routine screening during hospitalization to identify comorbid depression provides an 
opportunity to initiate collaborative depression management.  Despite evidence-based 
recommendations, routine depression screening and management are not always included in the 
management of patients with diabetes admitted to inpatient medical units.  
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Purpose  
 The purpose of this clinical demonstration study was to explore the feasibility of 
depression screening and follow-up for patients with diabetes during their hospitalization and to 
evaluate the effect of depression management in depressive symptoms, health-related quality of 
life, diabetes self-management and all-cause 30-day readmission rates of patients with diabetes. 
The following clinical questions were addressed: 
 Was it feasible to screen for depressive symptoms in patients with diabetes who 
were admitted to the Durham Veterans Affairs Medical Center (DVAMC) with 
medical problems?    
 Was it feasible for inpatient medical providers to initiate management and follow-
up for identified depressive symptoms in these patients? 
 Would patients with diabetes who also had depression be able to manage their 
diabetes better if they received treatment for their depression?  
 Would patients with diabetes who also had depression have a better quality of life 
if they received treatment for their depression?   
 Would management of depression among hospitalized patients with diabetes 
reduce emergency department visits for non-emergent conditions and re-
hospitalizations for ambulatory care sensitive conditions?  
 What were the challenges identified by inpatient medical providers in initiating 
management and follow-up for depressive symptoms? 
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CHAPTER 2: REVIEW OF LITERATURE 
Search Strategy 
Databases used for this literature search included PubMed, Cumulative Index to Nursing 
and Allied Health Literature (CINAHL), Academic search premier, Social work abstracts, and 
Applied Social Sciences Index and Abstracts.  This literature search was limited to manuscripts 
published in English from January 1, 2005, to August 30, 2015.  Search terms included diabetes, 
depression, prevalence, management, diabetes distress, emotional problem, and mental health.  
Inclusion criteria included studies examining the prevalence of depression among adults with 
known diabetes, studies on the effects of depression on glycemic control, and the effects of 
collaborative depression management.  Exclusion criteria included studies limited to 
pharmacotherapy; studies comparing the prevalence of depression in patients with chronic 
diseases in general, studies examining the effect of race and ethnicity in depression, studies 
comparing the utility of different depression screening tools, and studies conducted among 
adolescents.  
Prevalence of Comorbid Depression  
The relationship between diabetes and depression has been noted in the literature for over 
300 years, and evidence suggests a bi-directional relationship between depression and type 2 
diabetes (Egede & Ellis, 2010; Mezuk, Eaton, Albrecht, & Golden, 2008; Semenkovich, Brown, 
Svrakic, & Lustman, 2015).  To date, there have been multiple competing theories on the reason 
why patients with diabetes develop depression. Behavioral health has applied Beck’s cognitive 
theory to conceptualize the development of depression (Beck, 2008).  Daily challenges related to 
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lifestyle modification, blood glucose monitoring and adherence to medication and diet place a 
huge demand on patients.  Patients’ struggle to maintain adherence may lead to frustration and 
negative thoughts.  Inability to generate better outcomes such as weight loss or lower blood 
glucose levels may aggravate these thoughts.  Some individuals may use their defense 
mechanisms and social and spiritual support systems to control these negative thoughts.  
Uncontrolled negative thoughts can lead to helplessness and hopelessness (Henkel, Bussfeld, & 
Möller, 2002; Joiner et al., 2001).  People with a pessimistic explanatory style may view the 
cause of negative outcomes as internal and develop depression when dealing with negative 
experiences. As per Aaron Beck’s cognitive theory of depression (Beck, 2008), negative 
thoughts lead to dysfunctional belief themes or schemas such as the person is defective or 
inadequate, everything results in failure, and the future is hopeless which constitute the negative 
cognitive triad.  Individuals who cannot process this cognitive triad develop depression. 
Also, others theorize that patients diagnosed with diabetes experience lifestyle alterations 
as a result of economic concerns, the duration of diabetes, the complications of diabetes, and 
poor quality of life, and these cumulative effects contribute to the risk of developing depression 
(Hamer, Batty, & Kivimaki, 2011).  All patients with diabetes do not develop depression; 
however, negative affect, negative life experiences and diabetes-related concerns predict future 
chances for developing major depression (Naranjo, Fisher, Areán, Hessler, & Mullan, 2011).  
Theories in Psychoneuroimmunology explain mechanisms by which experiences in the 
external social environment transduce to the internal biological environment and contribute to a 
depression pathogenesis (Nouwen, 2015).  There are several common neuroendocrine and 
neurotransmitter abnormalities related to both diabetes and depression (Nouwen, 2015; Siddiqui, 
Jha, Waghdhare, Agarwal, & Singh, 2014).  According to Social Signal Transduction Theory of 
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Depression (Slavich & Irwin, 2014), social stressors such as social rejection, isolation, exclusion 
and social adversity up-regulate the immune system, which leads to the production of pro-
inflammatory cytokines.  These cytokines signal the brain to induce behavioral and emotional 
changes leading to depression.  These mechanisms explain how social stressors and chronic 
inflammation in patients with diabetes increase vulnerability to comorbid depression. 
As compared to adults without diabetes, the prevalence of depression is significantly 
higher among patients with diabetes (Ali, Stone, Peters, Davies, & Khunti, 2006; de Groot, 
Doyle, Hockman, Wheeler, & al, 2007; Nouwen et al., 2010).  However, there is no established 
association between severity of diabetes and extent of depressive symptoms.  So symptoms of 
depression could be due to diabetes burden rather than impaired glucose metabolism (Knoll et 
al., 2007).  Lopez-de-Andrés et al. (2015) evaluated the prevalence of depression among 
hospitalized patients with diabetes from 2001 to 2011 and reported an increased prevalence of 
depression even though there were improvements in their health profile and a decreased length of 
stay during that period.  Patients with comorbid depression can have serious complications of 
diabetes as compared to patients who have diabetes alone.  Depression affects patients' health-
related quality of life, self-care, and ability to communicate effectively with health care providers 
or seek resources to manage their diabetes (Katerndahl, Calmbach, & Becho, 2012), which 
affects their diabetes care outcomes. 
Effects of Comorbid Depression  
Comorbid depression affects various aspects of diabetes self-management.  Poor self-
management and poor outcomes in these patients are well-documented (Lin et al., 2010; Shah, 
Mezzio, Ho, & Ip, 2015; Solis, 2011; Vickers, Nies, Patten, Dierkhising, & Smith, 2006; 
Waitzfelder et al., 2010).  There is a reciprocal relationship between depressive symptoms and 
self-efficacy in patients with diabetes (Adam & Folds, 2014) and these patients often perceive an 
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inadequate control over their diabetes (Egede & Ellis, 2010).  DiMatteo, Lepper, and Croghan 
(2000) identified a three-fold risk for non-adherence among patients with diabetes and comorbid 
depression as compared to those who have diabetes alone.  Even minor depression is associated 
with poor self-management (Gonzalez et al., 2007), which leads to physical disability 
(Deschênes, Burns, & Schmitz, 2015; Lysy, Da Costa, & Dasgupta, 2008).  Richardson et al. 
(2008) suggested that there is a longitudinal relationship between depression and poor glycemic 
control and confirmed the association between depression and high glycated hemoglobin 
(HbA1c) levels over time.  Comorbid depression may act as a catalyst in the progression of 
diabetes and development of cardiovascular complications (Cummings, et al., 2016; Singh et al., 
2015).  Increased risk of mortality in patients with diabetes and comorbid depression is well 
supported (Coleman, Katon, Lin, & Von Korff, 2013; Katon et al., 2008; Kimbro, Steers, 
Mangione, Duru, & Ettner, 2014; Park, Katon, & Wolf, 2013; Sullivan et al., 2012).  Bogner and 
colleagues (2007) reported a reduction in five-year mortality with appropriate management of 
underlying depression in older adults with diabetes.   
Patients with diabetes and comorbid depression have a higher risk for missed preventive 
self-care practices (Egede, Grubaugh, & Ellis, 2010) leading to a higher risk for retinopathy 
(Sieu et al., 2011), lower limb amputations (Williams et al., 2011), and hypoglycemic episodes 
(Katon et al., 2013).  Also, patients with diabetes exhibit hyperglycemia associated brain injury, 
cognitive decline and memory impairment (Weinstein et al., 2015), which increases their risk of 
dementia.  Köhler and colleagues (2015) reported a high risk of dementia in patients with 
depression.  However, patients with diabetes and comorbid depression have an increased risk for 
dementia compared to patients with either of these disease conditions alone (Katon et al., 2015).  
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The presence of depression has a significant economic impact on diabetes care.  Patients 
with diabetes and comorbid depression tend to report poor health-related quality of life (Egede & 
Hernández-Tejada, 2013; Katerndahl, et al., 2012) and more physical symptoms which lead to 
more hospitalizations for ambulatory care sensitive symptoms (Davydow et al., 2013; 
Subramaniam et al., 2009).  Public health research also endorses increased physical symptoms, 
higher utilization of healthcare services and preventable hospitalizations among these patients 
(Smith, Gariepy, & Schmitz, 2014).  A higher number of office visits, emergency room visits, 
hospitalizations and prescription usage led to higher health care costs in this patient population 
(Kalsekar et al., 2006).  Simon and colleagues (2005) reported a 50-75% increase in health care 
costs in patients with diabetes and depression.  According to a multi-morbidity disease cluster 
cost analysis in the Veterans’ Health Administration, diabetes with depression accounts for the 
highest healthcare expenditures (Egede et al., 2015).  
Globally, after controlling for gross domestic product (GDP) per capita, the U.S. has the 
highest diabetes-related health care costs (Seuring, Archangelidi, & Suhrcke, 2015).  In regards 
to health care spending, loss of productivity related to physical or psychological symptoms 
increases the financial burden.  Egede (2004) analyzed the 1999 National Health Interview 
Survey for the prevalence of functional disability.  According to this analysis, the prevalence of 
functional disability was 24.5% for participants without diabetes or depression, 51.3% for those 
with major depression, 58.1% for those with diabetes and 77.8% of participants with diabetes 
and depression (Egade, 2004).  In 2012, the estimated total cost of diabetes in the United States 
was $245 billion, which included an estimated $176 billion in direct health care costs and $69 
billion related to reduced productivity (Economic Costs of Diabetes, 2013).  Simon et al. (2007) 
analyzed the economic benefit of symptom-free days and reported a cost benefit of $952 per 
 9 
patient over a 24-month period when patients received adequate management for their comorbid 
depression.  
According to Schierhout and colleagues (2013), depression in patients with diabetes is 
often unidentified or inadequately treated.  The unidentified depression may be related to several 
factors.  Comorbid depression may be considered as secondary to medical illness and viewed as 
less severe.  Providers might focus on physical illness and ignore depressive symptoms.  The 
overlap of physical symptoms may make the diagnosis of comorbid depression challenging.  
Patients may think it is normal to feel sad while having a chronic illness such as diabetes and 
may not consider it as depression and may not report to their providers.  Li et al. (2009) analyzed 
data from the Behavioral Risk Factor Surveillance System and reported that nearly 45% of 
patients with diabetes had undiagnosed depression.  The ADA (2016) supports routine screening 
for depression as part of standard diabetes management.  Screening for depression at the time of 
diagnosis of diabetes, during routine follow-up visits, on initiation of insulin, during 
hospitalization, and at the onset of any complications can identify the symptoms of depression 
(ADA, 2016).   
Effect of Collaborative Management of Co-Morbid Depression 
The effect of depression management on improvement in HbA1c has not been established 
(Georgiades et al., 2007; Katon et al., 2004; Wang, Tsai, Chou, & Chen, 2008).  However, 
Nicolau and colleagues (2013) reported improved health-related quality of life with improvement 
in comorbid depression.  Outcomes of successful diabetes management depend not only on 
improved physiological indicators but also on symptom relief, improvement in social 
functioning, mental health and physical well-being (Safa et al., 2007).  Therefore, improvement 
in health-related quality of life is an important indicator of successful diabetes self-management. 
Chronic disease management has several dimensions and self-management is one of the four 
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strategic goals listed in Department of Health and Human Services’ framework for improving 
health status with chronic diseases (Parekh, Goodman, Gordon, & Koh, 2011).  Since patients 
with comorbid depression report more diabetes symptoms and utilize emergency room services 
more often for non-urgent medical conditions (Georgiades et al., 2007; Katon et al., 2006; Simon 
et al., 2007), management of depressive symptoms may improve diabetes symptoms and 
decrease emergency room visits and hospitalizations for non-urgent medical conditions. 
Additionally, there is evidence of improved mortality rates in patients with diabetes who 
received management for their comorbid depression (Bogner et al., 2007; Bogner et al., 2016).  
Providers who are involved in the management of diabetes can identify and initiate management 
for comorbid depression.  As Knowles et al. (2015) describe, collaborative management initiated 
by medical providers is an opportunity for patients to overcome the stigma associated with 
depression and seek professional support for their depressive symptoms.   
Gaps in the Literature 
A Cochrane Review on the effect of depression management in patients with diabetes and 
depression (Baumeister, Hutter, & Bengel, 2012) found that there was moderate improvement in 
glycemic control and depressive symptoms.  However, the effect of management of comorbid 
depression on quality of life, self-management and diabetes complications has not been 
sufficiently studied.  The review concluded that evidence was sparse and inconclusive due to a 
lack of well-designed studies.  Generation of evidence by future well-designed studies exploring 
the effect of management of depressive symptoms on glycemic control, self-management, and 
quality of life is a priority.  Additionally, future research needs to generate evidence on 
interventions capable of improving depression, diabetes-dependent quality of life and glycemic 
control.   
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Gaps in Clinical Practice  
Existing barriers in implementing depression care account for gaps in practice.  Several 
barriers exist in implementing routine depression screening and integrating collaborative 
depression care into diabetes self-management.  Osborn, Kozak, & Wagner (2010) identified 
various factors related to provider and patients which were potential barriers in integrating 
depression management in diabetes care.  System level concerns such as time constraints, 
competing for clinical expectations, general practitioners’ reluctance in initiating depression care 
and difficulty in collaborating with mental health care are potential barriers.  The indication of 
depression management is strong enough to overcome the system barriers.  The stigma 
associated with mental illness may prevent patients from reporting these symptoms and seeking 
professional help.  In hospitalized patients, inpatient providers can address depression and 
arrange primary care follow-up, which may decrease patient resistance in seeking professional 
help.  A patient-centered approach focused on potential benefits regarding the quality of life and 
improvement in physical and emotional symptoms may reduce patient resistance to depression 
management (Riley, McEntee, Gerson, & Dennison, 2009).  
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CHAPTER 3: THEORETICAL FRAMEWORK 
Diabetes is a chronic disease. The World Health Organizations’ (WHO) Innovative Care 
for Chronic Conditions (ICCC) framework emphasizes the importance of prepared and 
motivated patients as micro-level building blocks in the successful management of any chronic 
disease and conceptualizes patient’s quality of life as a primary outcome of disease management 
(WHO, 2002). According to the Chronic Care Model (CCM), better chronic disease outcomes 
are achieved when productive interactions took place between prepared and proactive practice 
team and empowered and prepared patients (Bodenheimer, Wagner, & Grumbach, 2002).  Self–
management support is one of the six key areas identified in CCM to improve chronic disease 
management (Baptista et al., 2016). 
The success of diabetes management depends on effective self-management.  Self-
management is one of the four strategic goals listed in Department of Health and Human 
Services framework for improving health status with chronic diseases (Parekh, Goodman, 
Gordon, & Koh, 2011).  Self-management refers to the dynamic, interactive, and daily processes 
in which individuals engage to manage a chronic illness (Ruggiero et al., 1997).  Grey, Knafl, & 
McCorkle (2006) defined self-management as a cluster of daily activities of an individual 
intended for managing a disease condition.  Self-management is a broad term which depicts the 
complex nature of living with a chronic condition such as diabetes.  Self-management 
incorporates the individual’s utilization of health care, lifestyle modification and efforts to 
monitor and manage disease (Grey, Knafl, & McCorkle, 2006).  
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This study was based on the hypothesis of the existence of unidentified comorbid 
depression among patients with diabetes as a barrier to their self-management.  The Revised Self 
and Family Management Framework explains the importance of reducing and eliminating 
potential barriers to improving outcomes of chronic disease management. 
The Revised Self and Family Management Framework 
According to the Revised Self and Family Management Framework (Grey, Schulman-
Green, Knafl, & Reynolds, 2015), various factors affect self-management of a chronic disease 
such as diabetes and influence disease management outcomes.  Identification of those facilitators 
and barriers may help the clinicians empower patients in employing successful self-management 
strategies.  Various tasks and skills related to self-management are identified as processes in this 
framework.  Effective self-management results in proximal outcomes which lead to distal 
outcomes (Grey et al., 2015). 
Application of the Revised Self and Family Management Framework  
According to the Revised Self and Family Management Framework (Grey et al., 2015), 
there are barriers and facilitators which affect self-management.  Comorbid depression, a highly 
prevalent condition in patients with diabetes acts as a barrier and negatively affects patients’ 
motivation, emotions and lifestyle patterns.  Comorbid depression leads to poor self-management 
of diabetes such as adjusting to psychosocial needs, dealing with self-monitoring, managing 
medications, maintaining diet and physical activity, navigating through the healthcare system 
and having meaningful engagement with the health care team (Grady & Gough, 2014).  Poor 
self-management leads to complications of diabetes (Shah et al., 2015; Waitzfelder et al., 2010).  
Higher incidence of diabetes symptoms and utilization of healthcare services may affect the 
patients’ quality of life which may increase their depression symptomatology and in turn worsen 
their motivation and emotions (Egede & Hernández-Tejada, 2013; Katerndahl, et al., 2012). This 
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vicious cycle potentially affects the overall quality of life, disease outcomes and health care 
costs.  Identification of depression is the initial step in eliminating this potential barrier.   
According to the Revised Self and Family Management Framework (Grey et al., 2015), 
there are three types of processes guiding self-management.  Processes include those focusing on 
illness needs such as learning, taking ownership and health promotion activities, processes for 
activating resources such as health care, spiritual, psychological and community resources and 
processes involved in living with diabetes such as processing emotions, finding meaning, and 
adjusting to the disease.  Depression negatively influences an individual’s desire to assume 
ownership of self-management and motivation to learn self-management activities (Adam & 
Folds, 2014; Egede & Ellis, 2010).  The presence of depression may impair a person’s ability to 
problem solve, approach and avail assistance and to advocate for self.  Control of depression will 
facilitate these processes of self-management and may lead to better outcomes.   
The Revised Self and Family Management Framework (Grey et al., 2015) conceptualizes 
self-management behaviors as proximal outcomes and improvement in health status and quality 
of life as distal outcomes.  Proximal outcomes correspond to an improvement in behaviors such 
as motivation and adherence to self-management, control of symptoms such as stress, pain, 
fatigue, sleep, physical activity and activities of daily living.  Proximal outcomes lead to distal 
outcomes.  Distal outcomes for individuals include control of disease complications, reduction in 
morbidity and mortality, and improvement in individual’s psychological well-being and quality 
of life.  For the healthcare system, the distal outcomes are improved access to health care, 
appropriate utilization of health care services and cost effectiveness.  Outcomes measured in this 
scholarly practice study are the severity of depressive symptoms, health-related quality of life 
(HRQoL), and re-admissions. 
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CHAPTER 4: METHODOLOGY 
Management of Comorbid Depression in Veterans with Diabetes was a demonstration 
study conducted from July 28, 2016, through December 31, 2016, in the medical-surgical units 
of Durham Veterans Administration Medical Center (DVAMC).  
Study Design 
The goal of this clinical demonstration study was to examine the feasibility and effect of 
depression screening and management in patients with diabetes during their hospitalization for 
medical illness.  This study included screening for depression, health-related quality of life 
(HRQoL) and diabetes self-management.  Providers were involved in initiating interventions to 
manage depression.  At the completion of the study, participants were rescreened for depression, 
health-related quality of life (HRQoL) and diabetes self-management. 
The specific goals of the study were:  
 To evaluate the feasibility of depression screening and initiation of depression 
management for patients with diabetes admitted to the DVAMC with medical 
illness. 
 Evaluate the effect of depression management on depressive symptoms, diabetes 
self-management, HRQoL, and health care utilization. 
Setting 
This Doctor of Nursing practice (DNP) scholarly study setting was located within the 
inpatient medical-surgical units at the local Veteran Affairs Medical Center (VAMC).  The 
VAMC shares the mission of the Veterans Health Administration which is honoring America’s 
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veterans with exceptional care delivered by collaborative teams which support continuous 
improvement (Mission, Vision, Values, 2012).  The core values of the VAMC include Integrity, 
Commitment, Advocacy, Respect, and Excellence (I CARE) and reflects its efforts to keep 
Lincoln’s promise to all “who shall have borne the battle.”  The philosophy and mission 
statement of the VAMC aligns with the practice change this study addresses.  The stakeholders 
of this study included veterans, their families, health care providers in the hospitalist team, 
clinical psychologists, mental health providers, and primary care providers. 
The DVAMC is a 274-bed tertiary care referral, teaching and research facility affiliated 
with major universities in North Carolina.  The medical center provides medical, surgical, mental 
health inpatient and outpatient services.  DVAMC is a major referral center for veterans residing 
in nearby states.  In the fiscal year 2015, the DVAMC had 61,704 veterans in primary care which 
include 12,900 veterans with diabetes.  In addition to outpatient services, veterans use DVAMC 
for their inpatient needs.  There are ninety-six beds assigned to four medical-surgical units which 
are utilized by patients admitted to medicine or surgery services.  Various medical teams are 
involved in the management of these patients as primary teams.  This study included patients 
admitted to the hospitalist teams.  Hospitalist teams consist of five advanced practice providers 
(nurse practitioners and physician assistants) and eight attending medical doctors including the 
two session chiefs.  The hospitalist service has an average of 18.9 admissions per week.  Patients 
are admitted with acute medical concerns or for acute exacerbations or complications of chronic 
medical illnesses.  Diabetes is a common medical condition in this population. The average 
length of stay for these patients is 5.6 days. 
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Sample 
Participants of this study included a convenience sample of seven veterans aged 18 and 
above, admitted to hospitalist medical teams during the study period with a primary diagnosis of 
type 2 diabetes and a HbA1c of 7.0% or higher.  However, two participants were lost to follow-
up due to death and the data collected from five participants who completed the study is reported 
here.   Patients admitted to other teams, patients who did not have a known diagnosis of type 
2diabetes or who had type 2 diabetes with HbA1c of less than 7.0%, patients who were currently 
receiving treatment for depression and cognitively impaired patients were excluded from the 
study. 
Screening Tools  
There are several instruments available for screening for depressive symptoms and for 
evaluating diabetes self-management and HRQoL.  The instruments used in this study included 
the Patient Health Questionnaire – 2 (PHQ-2) (Kroenke, Spitzer, Williams, 2003), the Patient 
Health Questionnaire – 9 (PHQ-9) (Kroenke, Spitzer, & Williams, 2001), the Veterans RAND 
(Research and Development) 12-item Health Survey (VR-12) (Kazis et al., 2006), and the 
Stanford Diabetes Questionnaire (English Diabetes Research Instruments, 2016).  These 
instruments (see Appendices A, B, C, and D) are widely used in clinical practice and research.  
The PHQ and VR-12 are used at the Veterans health care system by various specialties and are 
built into its electronic health record.  
 Patient Health Questionnaire (PHQ).  Both the PHQ-2 (see Appendix A) and the PHQ-
9 (see Appendix B) are used widely to screen for depression (Arroll et al., 2010).  The PHQ- 2, a 
two-item questionnaire uses the first two questions from the PHQ-9.  These two questions 
inquire about anhedonia and depressed mood and are helpful as a quick screen for depressive 
symptoms.  Patients who scored three or higher on PHQ-2 screening were given the PHQ-9 
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evaluation to assess the severity of depressive symptoms (Jin, Wu, & Di Capua, 2015; Kroenke, 
Spitzer, Williams, 2003).   
The PHQ-9 is a self-reported questionnaire consisting of nine questions which inquire 
about depressive symptoms such as anhedonia, depressed mood, suicidality and physical 
symptoms caused by depression (Kroenke, Spitzer, & Williams, 2001).  These nine questions 
fulfill the criteria used for diagnosis of depression by Diagnostic and Statistical Manual of 
Mental Disorders, Fifth Edition (DSM-5) criteria (Trangle et al., 2016).  The questionnaire asks 
about symptoms such as lack of interest or pleasure in doing things, feeling down or depressed, 
or hopeless, problems with sleep, feeling tired or having lack of energy, problems with appetite, 
feeling bad about themselves, trouble concentrating on things, moving or speaking slowly that 
concerned others or feeling restless, and thoughts that they were better off dead and thought of 
self-harm.  Patients reported the degree at which they were bothered by these symptoms for the 
past two weeks. They rated the frequency of these symptoms using a scale ranging from 0-3 
where 0= not at all, 1= several days, 2= more than half the days, and 3= nearly every day.  The 
sum of the scores of the responses to the nine questions gave the PHQ-9 score.  Participants were 
also asked how difficult had these problems made it for them to do their work, take care of things 
at home, or get along with other people and they rated the difficulty as not difficult at all, 
somewhat difficult, very difficult, or extremely difficult. 
The possible PHQ-9 total score ranges from 0-27, and the severity is classified as 
follows: PHQ-9 scores up to 4 represent minimal depression, 5-9 mild depression, 10-14 
moderate depression, 15-19 moderately severe depression and 20-27 severe depression 
(Kroenke, Spitzer, & Williams, 2001).  Trangle and colleagues (2016) reported that PHQ-9 
scores of 10-14 correspond to mild major depression, 15-19 corresponds to moderate major 
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depression and ≥ 20 corresponds to severe major depression.  Kroenke and colleagues (2001) 
examined the validity of PHQ-9 by comparing the results with mental health professional 
interview outcomes and reported an 88% sensitivity and specificity for major depression with 
PHQ-9 scores of 10 or higher.  Wittkampf et al. (2009) evaluated the accuracy of the PHQ-9 in 
primary care settings and reported a sensitivity of 0.93 and specificity of 0.85 for screening 
depressive symptoms.  Eun Jin, Hall, & Moser (2014) evaluated the reliability and validity of 
PHQ-9 in patients with medical co-morbidities and supported the reliability (Cronbach's alpha 
0.87) and excellent concurrent validity with the Beck Depression Inventory (r = .78, p < .01). 
Veterans RAND 12-Item Health Survey (VR-12).  The VR-12 is a health survey 
questionnaire (see Appendix C) used to evaluate health-related quality of life (Kazis et al., 2006).  
It has been used in several large studies conducted by veterans’ health administration and in 
Medicare Outcome Surveys (Dobscha et al., 2009; Hsiao et al., 2012; Kazis et al., 2012; Kent et 
al., 2015). The VR-12 was developed from the VR-36, the 36-item survey which was used in 
main studies in the Veterans Health Administration (Iqbal et al., 2007). This 12-item self-
reported survey addresses eight domains of physical and mental health such as general health 
perceptions, physical functioning, and activity limitations due to physical and emotional 
problems, pain, fatigue, social functioning and mental health.  These components are weighed by 
the scoring computer program which provides a physical health summary measure called the 
Physical Component Summary (PCS) and a mental health summary measure called the Mental 
Component Summary (MCS) (Iqbal et al., 2007).  The PCS and MCS scores are standardized 
using a t-score transformation.  Higher physical component summary and mental component 
summary reflects better health-related quality of life (Kazis, et al., 2012; Selim, et al., 2009).  A 
recent Medicare outcome study reported average PCS and MCS scores of 39.82 (SD+12.2) and 
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50.08 (SD+11.4) respectively (Selim et al., 2009). These scores represent the current normal PCS 
and MCS for clinical applications.  Kazis and colleagues (2006) proposed that change by 1-2 or 
more points in MCS or PCS may be considered a clinically relevant change.  In the Veterans 
Health Administration, the difference in the PCS and MCS scores in VR-12 is used to evaluate 
the clinical impact of intervention on outcomes (Iqbal et al., 2007).  The Medicare Outcome 
Survey (Health Services Advisory Group, 2006), the Managed Care Community Healthcare 
Access Program (CHAPS) Enrollee Survey and the Medicare Current Beneficiary Survey 
(MCBS) Cost and Use Data (Kazis et al., 2012) consider a one point improvement in the PCS to 
be associated with a 6% decrease in total health care expenditures whereas one point 
improvement in the MCS is associated with a 7% decrease in total health care expenditures 
(Health Services Advisory Group, 2006). 
Stanford Diabetes Questionnaire. This questionnaire (see Appendix D) consists of 
diabetes-specific questions to evaluate patient’s health behaviors, health status, health care 
utilization and self-efficacy. It was developed by the Stanford Patient Education Research Center 
and is available on the Stanford University website (English Diabetes Research Instruments, 
2016).  This self- reported survey includes questions about patient’s perception of general health, 
physical and emotional symptoms, influence of physical and emotional health on daily activities, 
diabetes self-management activities such as diet, glucose monitoring, management of low and 
high blood glucose, medications, follow-up visits and patient’s confidence in managing various 
dimensions of diabetes care (English Diabetes Research Instruments, 2016).  Though this survey 
is widely used, no studies were identified which reported the validity of this tool.   
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Survey to evaluate the feasibility of depression screening.  At the completion of the 
study, five participants answered the survey that explored their experience with depression 
screening (See Appendix E).  Participants were asked about what they liked about the study; 
whether they felt that they needed help with their depressive symptoms; whether they received 
any treatment for their depression; whether they talked to a psychologist for follow-up of their 
depressive symptoms; how they felt about knowing that they had depressive symptoms; whether 
they liked receiving telephone calls for follow-up interviews; whether they had any concerns 
about discussing depressive symptoms with the provider who managed their diabetes; their 
willingness to consult a mental health provider for their depressive symptoms; and their 
suggestions to better serve them in terms of managing their diabetes and depression.    
At the conclusion of the participant enrollment, an anonymous survey (See Appendix F) 
was distributed among the hospitalist providers. The survey was distributed among the 
hospitalist team providers irrespective of being involved in the study as a provider who initiated 
management for participants with depressive symptoms.  Of the thirteen providers, nine 
providers answered this voluntary survey.  The survey asked about what they liked or did not 
like about the study; whether they considered patients with diabetes have an increased risk for 
developing depression as compared to patients who do not have diabetes; whether they believed 
that screening and management of co-morbid depression needs to be integrated to management 
of patients with diabetes; whether they experienced any difficulty in managing patients with 
depressive symptoms; their confidence in managing depressive symptoms; and any suggestions 
for screening and managing co-morbid depression in hospitalized patients with diabetes.    
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Regulatory Approval and Ethical Concerns 
The Institutional Review Board (IRB) at the DVAMC granted approval after a full 
review and the University of North Carolina at Chapel Hill IRB gave approval after an expedited 
review.  Participants signed an informed consent (see Appendix G) and the authorization for the 
use and release of individually identifiable health information by the Health Insurance Portability 
and Accountability Act (HIPAA) (see Appendix H) before enrolling in the study.  Procedures 
were in place to ensure participants’ privacy.  All electronic data was coded and saved in the H 
drive at the DVAMC, and paper data was kept in a locked cabinet behind a locked door.  
Provider Engagement 
Before the study, the DNP student discussed the study protocol with the hospitalist team 
providers in a group education session during their team meeting held on July 4, 2016.  Of the 
thirteen providers, ten providers attended this information session.  The DNP student discussed 
the increased risk for comorbid depression in patients with diabetes and the effect of comorbid 
depression in their health-related quality of life, diabetes self-management, and diabetes 
outcomes.  The information session highlighted the study protocol and the expectations from the 
providers.  Site mentor, Brian Schneider, MD, chief of the hospitalist team explained the 
procedure for the providers to consult the primary care mental health integration service at the 
time of discharge to ensure outpatient follow-up of depressive symptoms.  The DNP student 
distributed laminated pocket cards (See Appendix I) with sections from Veterans Affairs/ 
Department of Defense (VA/ DoD) Clinical Practice Guidelines on the management of major 
depressive disorder.  These pocket cards included prescribing and monitoring information of 
common antidepressants.  The DNP student communicated positive depression screens to the 
providers via electronic health record.  As the participant enrollment in the study ended, the DNP 
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student distributed a survey questionnaire to the hospitalist team providers which inquired about 
their perception on managing depression and any barriers they encountered in the process.  
Procedures 
The participants of this study included a convenience sample of five veterans admitted to 
hospitalist medical team care from July 2016 to December 2016 with a primary diagnosis of type 
2 diabetes who screened positive for depression.  Patients admitted to other medical teams and 
those without type 2 diabetes were excluded from this study.  Cognitively impaired patients, 
patients who were suffering from delirium or those patients who could not provide a reliable 
response to the questionnaires were also excluded from the study.  Participation was voluntary.  
Patients who screened negative for depression were also excluded from the study.   
The DNP student identified potential participants from the electronic health records using 
the above inclusion criteria. The DNP student described the study in detail to the potential 
participant in a face-to-face, individual encounter and answered all questions before asking the 
participant if they wanted to sign the informed consent (See Appendix G).  Participants signed 
the authorization also for the use and release of individually identifiable health information 
collected for the research (See Appendix H). 
The DNP student then administered the PHQ-2.  If the patient screened negative for 
depression using the PHQ-2 (Kroenke, Spitzer, & Williams, 2001), they were excluded from the 
study.  Those patients who scored ≥ 3 on the PHQ-2 (Kroenke, Spitzer, & Williams, 2001) were 
enrolled in the study.  These participants received additional screening using the PHQ-9 
(Kroenke, Spitzer, & Williams, 2001) to quantify the severity of depressive symptoms.  The 
DNP student discussed the results of the screening with the participant and provided information 
materials on depression and depression management.  The patient information materials 
distributed were ‘What is Major Depression? A VA Fact Sheet providing information on basic 
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facts, symptoms, treatments, and information for families (2011)’ and ‘Depression: An easy-to-
read booklet that explains what depression is, how long it lasts and how to get help, National 
Institute of Mental Health (2013)’. The DNP student then administered the PHQ-9 (Kroenke, 
Spitzer, & Williams, 2001), the VR-12 (Iqbal et al., 2007) and the Stanford Diabetes 
Questionnaire (English Diabetes Research Instruments, 2016).  The DNP student then updated 
the inpatient provider about presence and severity of depression symptoms using the 
computerized patient record system (CPRS), the electronic health records used in the facility.  
The inpatient provider then discussed depression management options with the 
participant and made depression management plans honoring the participant’s choice.  
Depending on the severity of depressive symptoms and participant’s acceptance, the hospitalist 
provider made referrals to the mental health provider or prescribed antidepressants or both.  
Upon discharge from the inpatient unit, the participant received a schedule for a follow-up 
appointment with their primary care provider in 30 days.  The primary care provider continued to 
follow the participant’s severity of depressive symptoms and continued management during 
routine outpatient visits. 
Approximately eight weeks and twelve weeks following their discharge from the 
hospital, the DNP student contacted the participants via telephone.  During this telephone follow-
up, each participant was administered the PHQ-9 (Kroenke, Spitzer, & Williams, 2001), the VR-
12 (Iqbal et al., 2007) and the Stanford Diabetes Questionnaire (English Diabetes Research 
Instruments, 2016) over the telephone.  The PHQ-2, PHQ-9 (Kroenke, Spitzer, & Williams, 
2001) and the VR-12 (Iqbal et al., 2007) are part of the Computerized Patient Record System, so 
the scores of PHQ-2, PHQ-9 and VR-12 became part of their permanent health record. During 
the post-discharge follow-up calls, the participants were asked about any life events or stressors, 
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participant’s experience of depression screening and readiness to receive depression treatment 
and details of adherence to antidepressant medications.    
Data Analysis 
Descriptive statistics (means, standard deviations, range, and percentages) were used to 
describe the demographics, PHQ-9, VR-12 and the Stanford Diabetes Questionnaire scores.  A 
paired t-test was conducted to assess any change in mean PHQ-9, VR-12 and Stanford Diabetes 
Questionnaire scores.   
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CHAPTER 5: RESULTS 
Participant Enrollment 
Participant selection and enrollment in this study took place from July 2016 to December 
2016 in the inpatient medical units.  Computerized health records of (n=193) patients admitted to 
the hospitalist medicine team service were screened for eligibility.  Among the 193 charts 
screened, 35.8% of the patients (n=69) had a documented diagnosis of type 2 diabetes in their 
health records.  Medical records of these 69 patients were screened for recent HbA1c values.  All 
of these 69 patients (100%) had their HbA1c value recorded within the past three months of 
hospitalization, and 60.9% of these patients (n=42) had a HbA1c of 7.0% or higher and qualified 
for further review.  Seventeen patients (n=17) were excluded for various reasons (see Figure 1).  
Nine patients (n=9) declined to enroll in the study. Twenty-one patients (n=21) signed the 
informed consent, and the DNP student administered the PHQ-2 questionnaire (See Appendix 
A).  Seven patients (n=7) who had PHQ-2 scores ≥ 3 qualified for the study and enrolled in the 
study.  However, two of the participants were lost to follow-up due to death.  In the Electronic 
Health Record, the causes of their death were noted as natural causes and sepsis respectively.  
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Figure 1. Participant enrollment and completion of the study 
 
Of the 21 patients screened and consented for the study, seven patients qualified and enrolled in 
the study, and five participants completed the study 
Assessed for eligibility 
(n =193) 
Patients without Diabetes  
(n = 124)  
Patients with Diabetes  
(n = 69) 
HbA1C ≥7.0% 
(n=47) 
HbA1C <7.0% 
(n=22) 
Excluded (n= 17) 
Reasons for Exclusion 
1. Delirium (n= 2) 
2. Dementia (n=4) 
3. Aphasia (n= 1) 
4. Active mental health 
problems (n= 4) 
5. On treatment for 
depression (n= 4) 
6. Type 1 diabetes (n=2) 
Consented 
(n= 21) 
Positive for 
Depression 
(n=7) 
Negative for 
Depression 
(n=14) 
Lost follow-up due 
to death (n=2) 
Completed the 
study (n=5) 
Refused consent 
(n=9) 
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Demographic Data  
Twenty-one male participants were screened using the PHQ-2 questionnaire.  
Participants’ age ranged from 51 to 85 years (Mean= 67.2, SD + 7.5).  Of these 21 participants, 
61.9% were Caucasian (n=13), 28.5% were African American (n=6), 4.8% were Latino (n=1) 
and 4.8% were American Indian (n=1).  The HbA1c ranged from 7% to 13.2% (Mean = 8.2, SD 
+1.6).  Of the 21 participants screened for depression, 33.3% (n=7) had positive screens with a 
score ≥ 3. These seven patients were enrolled in the study (See Table 1).  Participants’ age 
ranged from 56 to 72 (Mean = 65.3, SD + 5.7). Of these seven patients, 57.1% were Caucasian 
(n=4), 14.3% were African American (n=1), 14.3% were Latino (n=1) and 14.3% were 
American Indian (n=1).  Of the seven participants, 57.2% were high school graduates (n=4), 
28.5% reported some college education (n=2) and 14.3% had a bachelor's degree (n=1).  HbA1c 
of these seven participants ranged from 7.0 to 13.2 (Mean = 8.8, SD + 2.3). 
Table 1. Demographic Characteristics 
Total consented (n=21) Total who met inclusion criteria (n=7) 
Age   Age   
Mean SD Range Mean SD Range 
67.2 7.5 51-85 65.3 5.7 56-72 
      
Race/ Ethnicity   Race/ Ethnicity   
 Number Percent  Number Percent 
Caucasian 13 61.9 Caucasian 4 57.1 
African American 6 28.5 African American 1 14.3 
American Indian 1 4.8 American Indian 1 14.3 
Latino 1 4.8 Latino 1 14.3 
      
HbA1c   HbA1c   
Mean SD Range Mean SD Range 
8.2 1.6 7-13.2 8.8 2.3 7-13.2 
      
PHQ-2      
 Number Percent    
<3 14 66.7    
≥3 7 33.3    
Abbreviations: HbA1c (Hemoglobin A1c); PHQ-2 (Patient Health Questionnaire-2 items);  
SD (Standard Deviation) 
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Depression Scores 
Participants (n=5) answered the Patient Health Questionnaire (PHQ-9) nine-item 
depression screening tool (Kroenke, Spitzer, & Williams, 2001).  For the five participants who 
completed the study, initial PHQ-9 scores ranged from 12 to 17 (Mean = 16, SD + 2.2).  Of the 
five participants, one participant (20%) scored in the range of 10-14 (moderate depression), four 
participants (80%) scored in the range of 15-19 (moderately severe depression).  All five 
participants received some intervention initiated by their provider and had post-discharge follow-
up plans arranged by the inpatient provider.  Four of these participants received antidepressants 
while inpatient and a prescription to continue the antidepressant after discharge.  One participant 
received an antidepressant and a few sessions of psychotherapy from a clinical Psychologist 
while receiving inpatient rehabilitation.  At the eight weeks follow-up, the PHQ-9 scores ranged 
from 1 to 16 (Mean = 8, SD + 7).  At eight weeks, three participants received a PHQ-9 score that 
ranged from 0-4 (minimal depression), one participant received a PHQ-9 score in the range of 5-
9 (mild depression), and one participant received PHQ-9 scores in the range of 15-19 
(moderately severe depression).  At 12 weeks, the participants’ PHQ-9 scores ranged from 1 to12 
(Mean = 4, SD + 4.6).  Of the five participants, three participants received PHQ-9 scores in the 
range of 0-4 (minimal depression), one participant received a PHQ-9 score in the range of 5-9 
(mild depression), and the other participant received a PHQ-9 score in the range of 10-14 
(moderate depression).  From Time 1 to Time 3, there was a significant improvement in PHQ-9 
scores (p = 0.017).   
At Time 1, depressive symptoms made it somewhat difficult for two participants (40%), 
very difficult for another two participants (40%) and extremely difficult for one participant 
(20%) to do their work or to take care of things at home, and to get along with other people.  At 
Time 2 and Time 3, two of the participants (40%) reported that these symptoms were not at all 
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making it difficult for them to do their work or take care of things at home or to get along with 
other people.  However, depressive symptoms continued to affect the other three participants 
(60%) and made it somewhat difficult for the participants to do their work or take care of things 
at home or to get along with other people.  None of the participants felt that depressive 
symptoms made it very difficult or extremely difficult for them to do their work or take care of 
things at home or to get along with other people due to depressive symptoms. 
Table 2. Depression and Quality of Life Outcomes (n=5) 
 
Time 1 
 
Mean±SD 
Time 2 (8 weeks) 
 
Time 3 (12 weeks) 
 
Mean±SD t p Mean±SD t p 
 
PHQ-9 
 
16.0±2.2 
 
8.0±7.0 
 
2.10 
 
0.128 
 
4.0±4.6 
 
4.87 
 
0.017 
 
PCS 
 
31.3±7.5 
 
32.5±10.2 
 
-1.28 
 
0.291 
 
39.86 ±10.0 
 
-7.01 
 
0.006 
 
MCS 26.18±3.4 44.72±9.6 -4.10 0.026 48.18±9.1 -4.60 0.019 
A lower PHQ-9 score indicates better mental health. Higher PCS and MCS scores indicate better 
health-related quality of life.  Bold p values indicate significance 
Abbreviation: Mental Component Summary (MCS); Physical Component Summary (PCS);  
Patient Health Questionnaire-9 items (PHQ-9) 
 
Health-Related Quality of Life 
Participants (n=5) answered the Veteran’s RAND-12-item questionnaire (Iqbal et al., 
2007).  They rated their general health as either poor, fair, good, very good or excellent; degree 
of activity limitations as not at all limited, limited a little or limited a lot; extent that their 
physical health and mental health affected their daily activities for the previous four months and 
resulted in lesser accomplishments and limitation in type of activities they wanted to do as none 
of the time, little of the time, some of the time, most of the time or all of the time; interference of 
pain with normal work both inside and outside home as not at all,  little bit, moderately, quite a 
bit or extremely; extent of feeling calm and peaceful over the previous four weeks as all of the 
time, most of the time,  good bit of the time, some of the time, a little of the time or none of the 
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time; extent of experiencing lot of energy as all of the time, most of the time,  good bit of the 
time, some of the time, a little of the time or none of the time; occasions when they felt 
downhearted or blue as all of the time, most of the time,  good bit of the time, some of the time, a 
little of the time or none of the time; interference of physical health or emotional problems in 
their social activities as all of the time, most of the time, some of the time, a little of the time or 
none of the time.  The last two questions asked the participants to compare their present physical 
health and mental health to those at a year ago as much better, slightly better, about the same, 
slightly worse or much worse.  The Computerized Patient Record System, the electronic health 
record used in the facility calculated the Physical Component Summary (PCS) and Mental 
Component Summary (MCS) from the VR-12 questionnaire responses. From Time 1 to Time 3, 
there were significant improvements in PCS (p=0.006) and MCS (p=0.019) scores. 
Diabetes Self-Management 
The Stanford Diabetes Questionnaire collected information on participants’ general 
health, symptoms, daily activities, blood glucose testing, physical activity, confidence about 
doing things, diet and medications, and utilization of medical care (Stanford Patient Education 
Research Center, 2016).  
 General health.  Participants (n=5) rated their general health on a scale 1 to 5 where  
1=excellent, 2=very good, 3=good, 4=fair and 5=poor.  At the beginning of the study (See Table 
3), participants rated their general health as fair or poor (Mean=4.2, SD+0.5).  By Time 3, there 
was a significant improvement in their general health (p=0.041), and participants rated their 
general health as either good or very good (Mean=2.6, SD+1.7).  
 Symptoms.  Participants (n=5) rated their symptom burden using different scales (See 
Table 3).  The first four questions inquired whether in the past month they were discouraged by 
their health problems, fearful about their future health, their health caused worries in their life, or 
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they were frustrated by their health problems.  Participants answered these questions on a scale 
of 0 to 5 where 0=none of the time, 1=little of the time, 2=some of the time, 3=good bit of the 
time, 4=most of the time, and 5=all of the time.  At the beginning of the study, participants 
reported that a good bit of the time they were discouraged by their health problems, some of the 
time they were fearful about their future health and a good bit of the time they worried about 
their health and were frustrated by their health problems.  At Time 2, the participants were 
worried about their health or were discouraged by their health problems a little of the time.  At 
Time 3, participants reported that none of the times they worried about their health or were 
frustrated by their health problems. 
 Questions 5 to 7 asked the participants to rate the severity of their symptoms such as 
fatigue, pain, and shortness of breath for the past two weeks using a scale 0-10 where 0=the 
absence of symptoms and 10=severe symptoms.  At Time 3, participants reported a significant 
decrease in the severity of their fatigue (p=0.028); however, pain (p=0.105) and shortness of 
breath (p=0.060) did not decrease significantly. 
 Questions 8 to 21 inquired about the presence of symptoms such as increased thirst, dry 
mouth, decreased appetite, nausea or vomiting, abdominal pain, frequent nocturia, blood glucose 
> 300, morning headaches, nightmares, night sweats, lightheadedness, shakiness or weakness, 
intense hunger or occasions when they passed out or fainted.  Participants reported the presence 
of these symptoms for the past two weeks period as 0-2 where 0=no, 1=yes, 2=don’t know.  At 
Time 1, participants reported experiencing all these symptoms except intense hunger.  By Time 
3, participants reported to significant improvement in previously reported symptoms such as 
increased thirst (p=0.182), dry mouth (p=0.058), decreased appetite (p=0.182), nausea or 
vomiting (p=0.391), abdominal pain (p=0.182) frequent nocturia (p=0.182), blood glucose > 300, 
 33 
morning headaches (p=0.391), nightmares (p=0.182), night sweats (--), lightheadedness 
(p=0.058), shakiness or weakness (p=0.391), and passing out or fainting (p=0.182). 
 Daily activities. Participants (n=5) rated the interference of their health (See Table 3) in 
their normal social activities with family or friends, hobbies or recreational activities, household 
chores and errands for the past four weeks using 0-4 scale where 0=not at all, 1=slightly, 
2=moderately, 3=quite a bit, and 4=almost totally.  At Time 1, participants reported moderate 
interference of health in these activities.  By Time 3, participants reported a significant reduction 
of interference of their health in their normal social activities with family or friends  
(p=0.016), hobbies or recreational activities (p=0.010), household chores (p=0.030); however, 
there was no significant change in running errands (p=0.078). 
 Blood glucose testing. Participants (n=5) were asked (See Table 3) whether they had a 
blood glucose machine, how many days in the past week they tested their blood glucose and how 
many times they tested their blood glucose on an average day if they tested their blood glucose.  
All participants reported that they had a blood glucose machine and test strips at home.  By Time 
3, there was no significant increase in the number of days they checked their blood glucose 
(p=0.215) and no significant increase in number of times they checked their blood glucose in a 
typical day (p=0.1). 
 Physical activity. Participants (n=5) answered five questions (See Table 3) about the 
total time spend on different forms of exercises such as stretching or strengthening exercises, 
walking, swimming or aquatic exercise, bicycling and other aerobic exercises during a typical 
week using 0-4 scale where 0=none, 1=< 30 minutes/ week, 2=30-60 minutes/week, 3=1-3 
hours/week, and 4=> 3 hours/week.  Participants reported some stretching and walking as the 
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types of physical activities they did.  By Time 3, participants reported a significant increase of 
their time spent on walking as part of their regular exercise regime (p=0.003).  
Confidence about doing things. Participants (n=5) answered eight questions (See Table 
3) about their confidence in doing things and rated their present confidence level using a 1-10 
scale where 1=not at all confident and 10=very confident.  By Time 3, there was a significant  
improvement in the participants’ confidence that they could eat their meals every 4 to 5 hours 
including breakfast every day (p=0.003), follow their diet when they had to prepare and share 
food with other people who did not have diabetes (p=0.019), choose healthy snacks when hungry 
(p=0.019), exercise 15-20 minutes, 4 to 5 times per week (p=0.001), doing something to prevent 
their blood sugar from dropping when they exercised (p=0.031), judge changes in their health 
and make decisions to visit their health care providers (p=0.003), and control their diabetes so 
that diabetes wouldn’t interfere with the things they wanted to do (p=0.001). However, there was 
no significant different in their ability to institute measures when their blood sugar went higher 
or lower than it should be (p=0.099). 
 Diet and medications. Participants (n=5) were asked about the number of days they ate 
breakfast in the previous week (See Table 3).  At the initial screening, participants reported 
having breakfast 2-3 days per week, and by Time 3, they reported having breakfast on a daily 
basis.  Four questions (See Table 3) were asked about the usage of oral hypoglycemic agents, 
insulin, anti-hypertensives and lipid-lowering drugs in the previous week.  Across the study, 
there were no differences in medication use. 
 Medical care. Participants (n=5) answered eight questions about their utilization of 
medical care (See Table 3).  The first three questions inquired about their preparation and 
involvement in their medical visits and participants answered them using a 0-5 scale, where 
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0=never, 1=almost never, 2=sometimes, 3=fairly often, 4=very often, and 5=always.  At the 
beginning of the study, participants reported that they almost never prepared questions for their 
medical providers prior to the clinic visits.  At Time 3, participants did not report any significant 
difference in preparing questions for their medical providers prior to clinic visits or in discussing 
those personal problems which potentially affected their health with the providers.  Also, there 
were no significant improvements in the frequency of asking questions about their treatment and 
things which they did not understand about their treatment (p=0.098).   
The next five questions inquired about their utilization of health care services in the 
previous six months.  The questions asked for information on visits with health care providers, 
emergency department visits, hospitalizations, the length of stay in the hospital if they were 
hospitalized, and any stay in a skilled nursing facility or a convalescent center.  At Time 2 these 
questions focused on health care utilization during the period between Time 1 and Time 2.  
Similarly, at Time 3, these questions were focused on health care utilization during the period 
between Time 2 and Time 3.  At Time 1, the participants’ average emergency department visit 
was 2.6 (SD + 1.5).  At Time 2 follow-up, one of the participants was admitted to an inpatient 
unit for a planned lower extremity amputation.  Another participant was admitted for a planned 
adrenalectomy during the interval between Time 2 and Time 3.  No participants reported any 
unplanned hospitalizations.  Participants were asked about their preventive care such as foot 
examinations and eye examinations.  Participants did not report any differences in preventive 
care practices during the study period. 
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Table 3. Diabetes Self-Management Results (N=5) 
 Time 1 
(0 weeks) 
M±SD 
 
Time 2 (8 weeks) Time 3 (12 weeks) 
 
M±SD t p M±SD t p 
General health  
(scale 1-5) 
 
4.2±0.5 3.4±0.9 1.6 0.215 2.6±1.7 3.5 0.041 
Symptoms 
 
1. Were you 
discouraged by your 
health problems (past 
month)? (0-5) 
 
3.4±0.9 1.6±0.9 3.6 0.037 1.4±0.6 5 0.015 
2. Were you fearful 
about your future health 
(past month)? (0-5) 
 
1.8±1.5 1.2±1.1 1.6 0.215 0.4±0.6 1.7 0.181 
3. Was your health a 
worry in your life (past 
month)? (0-5) 
 
3.6±1.1 2±1.4 7 0.005 1.2±1.1 8.7 0.003 
4. Were you frustrated 
by your health problems 
(past month)? (0-5) 
 
3.2±0.8 1.8±1.1 4.9 0.016 0.8±0.8 7.35 0.005 
5. Describe your fatigue 
(past 2 weeks) (0-10) 
 
7.6±2.3 4.2±2.6 1.9 0.141 3.2±1.8 3.99 0.028 
6. Describe your pain 
(past 2 weeks) (0-10) 
 
6.2± 4.5 3.6±3.3 2.6 0.078 0 2.3 0.105 
7. Describe your 
shortness of breath (past 
2 weeks) (0-10) 
 
5.6±5.1 3.4±3.1 2.7 0.076 2.8±2.6 2.9 0.060 
8. Increased thirst (past 
week)? (yes/no) 
 
0.4±0.6 0 1.7 0.181 0 1.7 0.182 
9. Dry mouth (past 
week)? (yes/no) 
 
0.8±0.5 0 3 0.058 0.2±0.5 3 0.058 
10. Decreased appetite 
(past week)? (yes/no) 
0.6±0.6 0.2±0.5 1.7 0.182 0 1.7 0.182 
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 Time 1 
(0 weeks) 
M±SD 
 
Time 2 (8 weeks) Time 3 (12 weeks) 
 
M±SD t p M±SD t p 
11. Nausea or vomiting 
(past week)? (yes/no) 
 
0.4±0.6 0 1 0.391 0 1 0.391 
12. Abdominal pain 
(past week)? (yes/no) 
 
0.4±0.6 0 1.7 0.182 0 1.7 0.182 
13. Frequent urination 
at night at least three 
times (past week)? 
(yes/no) 
 
0.4±0.6 0 1.7 0.182 0 1.7 0.182 
14. Severely high 
(>300) blood glucose 
(past week)? (yes/no) 
 
0.8±0.5 0.4±0.6 1.7 0.182 0 - - 
15. Morning headaches 
(past week)? (yes/no) 
 
0.2±0.5 0 1 0.391 0 1 0.391 
16. Nightmares (past 
week)? (yes/no) 
 
0.4±0.6 0.2±0.5 1 0.391 0 1.7 0.182 
17. Night sweats (past 
week)? (yes/no) 
 
0.2±0.5 0 - - 0.2±0.5 - - 
18. Lightheadedness 
(past week)? (yes/no) 
 
0.8±0.5 0 3 0.058 0 3 0.058 
19. Shakiness or 
weakness (past week)? 
(yes/no) 
 
0.2±0.5 0 1 0.391 0 1 0.391 
20. Intense hunger (past 
week)? (yes/no) 
 
0.2±0.5 0 1 0.391 0 1 0.391 
21. Times when you 
passed out or fainted 
(past week)? (yes/no) 
 
 
 
 
 
0.4±0.5 0 1.7 0.182 0 1.7 0.182 
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 Time 1 
(0 weeks) 
M±SD 
 
Time 2 (8 weeks) Time 3 (12 weeks) 
 
M±SD t p M±SD t p 
Daily activities 
 
1. Has your health 
interfered with your 
normal social activities 
with family, friends, 
neighbors or groups 
(past 4 weeks)? (0-4) 
 
2.4±0.9 1.2±1.3 3.66 0.035 0.8±0.8 4.9 0.016 
2. Has your health 
interfered with your 
hobbies or recreational 
activities (past 4 
weeks)? (0-4) 
 
3±1 1.6±1.1 2.5 0.091 0.8±0.8 5.7 0.010 
3. Has your health 
interfered with your 
household chores 
(past 4 weeks)? (0-4) 
 
2.6±1.1 1.2±1.3 2.8 0.66 0.6±0.9 3.9 0.030 
4. Has your health 
interfered with your 
errands and shopping 
(past 4 weeks)?  
(0-4) 
 
2.4±1.5 1±1.2 2 0.133 0.4±0.9 2.6 0.078 
Glucose testing 
 
1. Do you have a 
machine to measure 
your blood glucose? 
(yes/no) 
 
1±0 1±0 - - 1±0 0 0 
2. How many days last 
week did you check 
your blood glucose? 
 
4.2±3.8 5.4±2.3 -1.6 0.215 4.8±3 -1.6 0.215 
3. On the days that you 
check your blood 
glucose how many days 
do you check on 
average? 
2.2±2.2 2.4±1.3 -.522 0.638 2.2±1.1 0 1 
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 Time 1 
(0 weeks) 
M±SD 
 
Time 2 (8 weeks) Time 3 (12 weeks) 
 
M±SD t p M±SD t p 
Physical activity (during the past week) 
 
1. Did you do stretching 
and strengthening 
exercises? (0-4) 
 
0 0.2±0.4 -1 0.391 1.2±-.8 -2.5 0.091 
2. Walk for exercise?  
(0-4) 
 
0 1.2±0.4 -5 0.015 2±1.2 -8.7 0.003 
3. Swimming or aquatic 
exercise? (0-4) 
 
0 0 - - 0 - - 
4. Bicycling (including 
stationary exercise 
bikes)? (0-4) 
 
0 0 - - 0 - - 
5. Other aerobic 
exercise (Stairmaster, 
rowing, skiing 
machine)? (0-4) 
 
0 0 - - 0 - - 
Confidence about doing things (at the present time) 
 
1. How confident are 
you that you can eat 
your meals every 4 to 5 
hours every day, 
including breakfast 
every day? 
(1-10) 
 
3.8±1.9 6.4±1.5 -6 0.009 7.6±2.3 -19.1 0.000
3 
2. How confident do 
you feel that you can 
follow your diet when 
you have to prepare and 
share food with other 
people who do not have 
diabetes? (1-10) 
 
3.4±2.3 6.8±1.8 -3 0.058 7.8±1.5 -4.6 0.019 
 40 
 Time 1 
(0 weeks) 
M±SD 
 
Time 2 (8 weeks) Time 3 (12 weeks) 
 
M±SD t p M±SD t p 
3. How confident do 
you feel that you can 
chose appropriate foods 
to eat when you are 
hungry (for example, 
snacks)? (1-10) 
 
3.6±2.3 6.8±1.8 -3 0.058 7.8±1.5 -4.6 0.019 
4. How confident do 
you feel that you can 
exercise 15 to 20 
minutes, 4 to 5 times a 
week? (1-10) 
 
1.6±0.9 3.2±1.6 -2.8 0.066 6.2±1.1 -12.3 0.001 
5. How confident do 
you feel that you can do 
something to prevent 
your blood sugar from 
dropping when you 
exercise? (1-10) 
 
4.6±2.9 7.6±2.1 -3.2 0.050 9.2±1.3 -3.9 0.031 
6. How confident do 
you feel you know what 
to do when your blood 
sugar goes higher or 
lower than it should be? 
(1-10) 
 
6±4.3 7.8±2.2 -2 0.141 9±1.7 -2.4 0.099 
7. How confident do 
you feel you can judge 
when the changes in 
your illness mean you 
should visit your 
doctor? (1-10) 
 
61.9± 8±2.4 -1.7 0.186 9.4±0.9 -9 0.003 
8. How confident do 
you feel that you can 
control your diabetes so 
that it does not interfere 
with the things you 
want to do? (1-10) 
 
3.6±1.7 7.4±2.3 -5.4 0.012 9.2±0.8 -12 0.001 
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 Time 1 
(0 weeks) 
M±SD 
 
Time 2 (8 weeks) Time 3 (12 weeks) 
 
M±SD t p M±SD t p 
Diet 
 
1. How many times last 
week did you eat 
breakfast when you got 
up? 
 
1.8±1.1 5±2.1 -5.4 0.012 6.6±0.9 -8.3 0.004 
Medications 
 
1. In the past week did 
you take pills for 
diabetes? (yes/no) 
 
0.6±0.5 0.6±0.5 - - 0.6±0.5 - - 
2. In the past week did 
you take insulin 
injections? (yes/no) 
 
0.6±0.5 0.6±0.5 - - 0.6±0.5 - - 
3. In the past week did 
you take pills for high 
blood pressure? 
(yes/no) 
 
1±0 1±0 - - 1±0 - - 
4. In the past week did 
you take pills for 
cholesterol? (yes/no) 
 
0.8±0.4 1±1 -1 0.391 0.8± 0.4 0 1 
Medical care 
 
1a. How often do you 
prepare a list of 
questions for your 
health care provider? 
(0-5) 
 
1.4±1.7 1.2±1.8 - - 1.4±1.9 -1 0.391 
1b. Ask questions about 
the things you want to 
know and things you 
don’t understand about 
your treatment? (0-5) 
 
2.8±1.6 3.2±1.3 -0.6 0.604 4.8±0.4 -2.4 0.098 
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 Time 1 
(0 weeks) 
M±SD 
 
Time 2 (8 weeks) Time 3 (12 weeks) 
 
M±SD t p M±SD t p 
1c. Discuss any 
personal problems that 
may be related to your 
illness? (0-5) 
 
2.2±1.6 1.8±0.4 0.2 0.840 3.8±1.8 -1.9 0.155 
2. In the past 6 months, 
how many times did 
you visit a health care 
provider? 
 
2.8±2.2 1.4±0.9 1.1 0.367 1.6±0.9 1 0.406 
3. In the past 6 months, 
how many times did 
you go to the hospital 
emergency department? 
 
2.6±1.5 0 3.2 0.048 0 3.2 0.048 
4. In the past 6 months 
how many times were 
you hospitalized for one 
night or longer? 
 
2.4±1.7 0.2±0.4 3.2 0.049 0.2±0.4 2.6 0.080 
5. How many total 
nights did you spend in 
the hospital in the past 6 
months? 
 
13.8±12.7 0.4±0.9 2.7 0.761 6.2±12.3 2.5 0.090 
6. Were any of these 
hospitalizations at a 
skilled nursing facility, 
convalescent hospital, 
or other minimum care 
facility? (yes/no) 
0.2±0.4 0 1 0.390 0.2±0.4 1 0.390 
Bold p values indicate significance.  
 
 
Feasibility of Depression Screening 
At the completion of the study, participants (n=5) answered the survey that explored their 
experience with depression screening (See Appendix E).  All five participants reported feeling 
that they needed help regarding their depression and all five participants received medications 
for their depressive symptoms.  Of the five, one participant received a few individual face to face 
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psychotherapy sessions with a clinical Psychologist.  Three out of five participants reported that 
they knew about their depressive symptoms and did not report them to their providers.  None of 
the participants reported having any concerns about the medical provider discussing their 
depressive symptoms or prescribing treatment for their depression.  Of the five participants, four 
participants preferred that their medical provider was managing their depression where as one 
participant had equal preference for medical and mental health provider.  One of the participants 
who preferred the medical provider reflected “I am not crazy.  I don’t want to see mental health.”  
None of the participants had any suggestions for improving the care of their diabetes or 
depression. Two of them felt they were receiving the “best medical care possible.” 
At the conclusion of the study, an anonymous survey (See Appendix F) was distributed 
among the hospitalist providers. Of the thirteen providers, nine providers answered this voluntary 
survey.  All nine providers (100%) reported that they consider patients with diabetes as having a 
higher risk for developing depression.  One provider did not consider this increased risk in the 
past; however, with this study and the provider learning session associated with the study, the 
provider now agrees with the increased risk for patients with diabetes to develop depression.  Of 
the nine providers who responded to the survey, 100% believed that depression screening and 
management needed to be integrated into the management of patients with diabetes.  Providers 
rated themselves regarding their confidence in initiating depression management as “confident” 
(33.3%), “fairly confident” (33.3%), “somewhat confident” (11.1%), “moderately confident” 
(11.1%) and “7/10” (11.1%).  Of the nine providers, three (33.3%) suggested that involving of 
mental health specialist through an electronic consult may improve the process of depression 
screening and management for hospitalized patients.  For improving the process of depression 
screening and management, four of the nine providers (44.4%) suggested adding PHQ-2 in the 
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standard admission screening, another four providers (44.4%) suggested routine depression 
screening in the outpatient setting and one provider (11.1%) did not offer any suggestions.  
Providers reported that they liked the information received in the provider education session 
conducted before the study, handouts/ pocket cards distributed to the providers (See Appendix 
G) and the alerts received about positive depression screens.  Two providers mentioned that the 
depression screen notes by the DNP student in the electronic health record were “easy to see” 
and “clear” whereas one provider considered these notes as “lengthy.”  One provider noted that 
the researcher was “very clear in approach and delivery and involved the team.” 
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CHAPTER 6: DISCUSSION 
The incidence of depression in patients with diabetes is higher than in patients without 
diabetes (Hasan, Mamun, Clavarino, Kairuz, 2015).  Patients with diabetes and comorbid 
depression report increased physical symptoms and higher utilization of emergency departments 
and preventable hospitalizations (Davydow et al., 2013; Smith, Gariepy, & Schmitz, 2014).  The 
purpose of this study was to explore the feasibility of depression screening and initiation of 
management for depressive symptoms in patients with diabetes while they are hospitalized with 
a medical illness and to evaluate the effect of depression management in their depressive 
symptoms, health-related quality of life, and diabetes self-management.  The results of this study 
support the feasibility of screening for depressive symptoms in hospitalized patients with 
diabetes. The findings from this study suggest that depression screening and initiation of 
management for depressive symptoms in patients with diabetes during their hospitalization may 
improve their depressive symptoms, health-related quality of life, and diabetes self-management.  
Also, the management of comorbid depression in patients with diabetes may decrease their 
emergency department use for non-emergent conditions and re-hospitalizations for ambulatory 
care sensitive conditions. 
Effect on Depressive Symptoms 
Over the study period, participants reported improvement in their depressive symptoms.  
The improvement in depressive symptoms in this study was similar to the improvement reported 
by Nicolau and colleagues (2013) in patients with diabetes who received medication 
management for their depressive symptoms.  Similarly, a Cochran review of psychological and 
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pharmacological interventions for depression in patients with diabetes reported clinically 
significant improvement in depressive symptoms (Baumeister, Hutter, & Bengel, 2014). In the 
current study, the improvement in depressive symptoms showed a noticeable trend over the 12 
week study period.  By the completion of the study, the improvement was statistically 
significant.  At baseline and at Time 2, participants’ depressive symptoms made it either 
extremely difficult or very difficult for them to do their work or to take care of things at home or 
to get along with other people.  Antidepressants require time and sometimes dosage adjustments 
to reach their full therapeutic effect, and during this period, patients may continue to experience 
depressive symptoms.  These findings endorse the importance of enhanced support from the 
clinician and health care team to ensure treatment adherence in patients with diabetes and 
comorbid depression.  However, at 12 months follow-up, Jani and colleagues (2015) did not 
identify a difference in depressive symptoms in participants who received antidepressants as 
compared to those participants who did not receive antidepressants.  Future studies need to 
examine the long-term outcomes of depression management on depressive symptoms.  
Effect on Health-Related Quality of Life 
Health-related quality of life refers to individuals’ perception of their physical, 
psychological, and social health and well-being (Speight, Reaney, & Barnard, 2009).  In the 
current study, data from Veteran’s RAND12 reports the health-related quality of life as Physical 
Component Summary (PCS) and Mental Component Summary (MCS) scores.  At baseline, the 
participants’ PCS and MCS scores were less than the population average. The lower PCS and 
MCS scores might reflect the poor physical health of the participants, especially when they were 
hospitalized for a medical illness.  However, the poor quality of life could also be due to 
depressive symptoms as there is a reciprocal relationship between severity of depression and 
health-related quality of life in patients with diabetes as reported by Timar and colleagues 
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(2016).  Over the study period, there were improvements in participants’ PCS and MCS scores.  
The improvement in MCS scores was beyond the improvement in PCS scores. This improvement 
in scores was very similar to the results from the Medical Expenditure Panel Survey analysis 
(Alenzi, Sambamoorthi, & Alenzi, 2016) where patients with diabetes and comorbid depression 
showed improvement in MCS scores, but not in PCS scores when their depressive symptoms 
were managed by antidepressants alone.  However, at the conclusion of the current study, there 
was a statistically significant improvement in PCS and MCS scores and thereby significant 
improvement in health-related quality of life.  Similar statistically significant improvements in 
health-related quality of life-related to the management of depressive symptoms in patients with 
diabetes and comorbid depression were reported by Nicolau and colleagues (2013) and Filipcić, 
Margetić, Simunović, & Jakovljević (2010).  Since the PCS and MCS scores showed 
improvement over the twelve week period, not at Time 2, the improvement may not be attributed 
entirely to participant not being in the hospital at the time of data collection.  Also, at Time 2, 
one of the five participants who completed the study and one participant who later lost follow-up 
were admitted to the hospital.  Of these two participants who were in the hospital at Time 2, the 
participant who later lost follow-up due to death had not received management for depression. 
This participant had a higher PHQ-9 score, lower PCS and MCS scores as compared to this 
participant’s baseline scores.  However, the other participant who was hospitalized at Time 2, 
received treatment for depressive symptoms had a higher MCS score compared to baseline, and 
the PCS score remained the same as the baseline score, which was similar to what Alenzi and 
colleagues (2016) reported. 
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Effect on General Health 
At the completion of the study, participants reported improvement in their general health.  
One can argue that when participants were hospitalized with a medical illness, they perceived 
their general health as poor, and once they were discharged from the hospital, they perceived 
better health.  In the current study, the perceived improvement in general health was not 
significant until Time 3 which indicates that not being hospitalized alone did not improve the 
participants’ perception of their general health.  Research supports individual’s self-rated poor 
health as a predictor for exacerbations and hospitalizations in patients with chronic diseases such 
as chronic obstructive pulmonary disease (Farkas, Kosnik, Flezar, Suskovic, & Lainscak, 2010) 
and heart failure (Creber, Allison, & Riegel, 2013). It is possible that patients with diabetes also 
have the increased risk for developing acute symptoms which require hospitalizations when they 
perceive poor general health.  Future studies examining the relationship between self-rated 
general health and hospitalizations in patients with diabetes may provide supporting data 
specifically for patients with diabetes. 
Effect on Symptoms 
At the completion of the study, participants reported statistically significant improvement 
in fatigue.  There was also an improvement in symptoms such as pain, polydipsia, hyperglycemia 
and symptoms of hypoglycemia.  However, participants continued to report physical symptoms 
such as shortness of breath, decreased appetite, nausea, vomiting, nocturia, and morning 
headache.  However, the health-related quality of life substudy of Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) trial analyzed the factors affecting diabetes 
symptoms and reported a significant association of current depressive symptoms (PHQ-9 score > 
10) with the severity of diabetes symptoms ( Sullivan et al., 2012).  In the current study, it is 
unsure whether the short follow-up period of 12 weeks was inadequate to influence the diabetes 
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symptoms.  Even though these symptoms persisted, participants reported less severity of these 
symptoms as compared to baseline.  At Time 3, though the participants continued to report 
certain symptoms, they were neither worried about their future health nor frustrated by their 
current health problems.  Participants’ positive approach to health and health problems may have 
resulted from their improved confidence in managing their diabetes. 
Effect on Confidence in Doing Things 
The study reported statistically significant improvement in participants’ confidence in 
performing several functions related to diabetes self- management.  A similar outcome was 
reported by Egede & Ellis (2008) and Ludman and colleagues (2013).  In the current study, 
participants lacked confidence in managing symptoms related to hypoglycemia and 
hyperglycemia though they reported confidence in preventing their blood sugars from dropping 
down.  Also, the improvement in confidence in choosing appropriate diet was not significant.  
Diet is an important aspect of diabetes self-management.  It is likely that several barriers such as 
personal preference, culture, social practices, access, and availability exist in following a 
therapeutic diet with modifications to keep optimum glycemic control.  Knowledge deficit may 
also affect the individual’s confidence in following the appropriate diet.  But, Egede & Ellis 
(2008) found that diabetes knowledge was not the determining factor in confidence related to 
diabetes self-management.  Gharaibeh, Gajewski, Al-smadi, & Boyle (2016) examined the 
relationships between depression, diabetes knowledge, self-care agency, self-efficacy and 
diabetes self- management.  In this study, self-care agency was defined as the individual’s 
capability to perform self-care activities whereas self- efficacy referred to cognitive, social and 
skills capability that a person has to perform a course of action (Gharaibeh et al., 2016).  This 
study identified a direct negative relationship of depression with self-care agency and self-
efficacy.  However, the effect of depression on diabetes self-management was not direct but 
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mediated by self-care agency and self-efficacy. Also depression did not affect diabetes 
knowledge.  So, improvement in self-efficacy and self-care agency is vital to improving self-
management.  Along with depression screening and management of depressive symptoms, 
activities to enhance patient self-care agency and self-efficacy may improve diabetes self-
management. 
Effect on Physical Activity 
Over the study period, participants did not report much physical activity.  At baseline, 
participants reported some walking as the main physical activity.  By Time 3, there was a 
significant improvement in time spent for walking for exercise.  Participants’ age, comorbidities, 
and symptoms such as shortness of breath might explain their reluctance to exercise. Physical 
activity is an important aspect of diabetes management.  Clinicians may improve patients’ 
physical activity by helping them identify potential activity modifications based on individual 
limitations and potentials.  As Gharaibeh and colleagues (2016) supported, the management of 
depressive symptoms alone may not improve patients’ diabetes self-management.  Innovative 
approaches such as involvement of a health coach (Wayne, Perez, Kaplan, & Ritvo, 2015), 
walking groups (Hanson, Guell, & Jones, 2015), psycho-social group interventions (Sabourin, 
Vallis, & Currie, 2011), and Whole Person Model of Disease-Self Management (Clarke, Baird,  
Perera, Hagger, & Teede, 2014) may improve physical activity in patients with diabetes and 
depressive symptoms.  Also, a patient-centered approach may improve patient’s adherence to 
physical activity recommendations.  
Effect on Daily Activities 
Manderson & Kokanovic (2009) reported the effect of diabetes on patients’ activities of 
daily living.  In the current study, at baseline, participants reported their health interfered with 
household activities, running errands, social and recreational activities.  Health-related 
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disengagement in social activities may be an early predictor of disability and death in older 
adults with diabetes (Kuo et al., 2004).  Over the study period, participants considered that health 
caused less interference in their activities.  This significant improvement might be an effect of 
improvement in their general health.  Also, the improvement in daily activities might have 
improved their health-related quality of life.  The improvement in functional ability related to the 
improvement in depressive symptoms may be sustainable if the participants continue to have 
improvement in their depressive symptoms as reported by Huang and colleagues (2012).  
Effect on Glucose Monitoring and Medication Adherence 
At baseline and throughout the study, the participants reported adequate blood glucose 
monitoring practices and appropriate medication adherence.  However, the literature supports the 
association between medication non-adherence and depression in patients with type 2 diabetes 
(Axon et al., 2016; Dirmaier et al., 2010; Gonzalez, Kane, Binko, Shapira, & Hoogendoorn, 
2016).  Medication non-adherence may apply to oral hypoglycemic agents, insulin, 
antidepressants and medications prescribed for other co-morbidities.  Shared decision making 
may improve patients trust in health care providers leading to improved medication adherence 
especially the adherence to antidepressants (Bauer et al., 2014).  Interventions to enhance social 
support may improve medication adherence in patients with diabetes and comorbid depression 
(Chew, Hassan, & Sherina, 2015; Kim et al., 2015; Osborn & Egede, 2012).  
Effect on Preventive Health Care 
Patients with diabetes and comorbid depression have a higher risk for missed preventive 
self-care practices (Egede, Grubaugh, & Ellis, 2010).  In the current study, at baseline, 
participants did not report appropriate preventive health care practices regarding annual 
ophthalmic or podiatry follow-up.  Over the study period, participants did not report attending or 
scheduling any ophthalmic or podiatry follow-up.  A short follow-up period of 12 weeks seems 
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to be inadequate for evaluating changes in preventive care practices with improvement in 
depressive symptoms.  
Health Care Utilization 
During the study period, there was no significant change in participants’ preparation for 
medical care visits such as preparing a list of questions or concerns about their health to discuss 
with their provider.  However, there was an improvement in participants’ interaction with 
providers regarding seeking an explanation of treatment or asking questions about their illness.  
One of the significant outcomes of this study is the decrease in participants’ emergency 
department use for non-emergent conditions and re-hospitalizations for ambulatory care sensitive 
conditions.  At baseline, all the participants reported minimum one emergency department visit 
in the previous month.  During the study period, none of the participants received care in 
emergency departments.  Two of the participants were hospitalized over the 12 week study 
period.  Both these participants were admitted for elective surgical procedures.  A significant 
reduction in re-hospitalizations for ambulatory care conditions in the participants could be due to 
improvement in their depressive symptoms.  Davydow and colleagues (2013) reported higher re-
hospitalization rates in patients with diabetes and depression.  Increased risk for re-
hospitalization for medical illness has been reported for patients with other chronic diseases 
when they also have comorbid depression as compared to patients with same chronic diseases 
who did not have depressive symptoms (Iyer et al., 2016; Kartha et al., 2007; Mitchell et al., 
2010; Cancino et al., 2014).  Pederson and colleagues (2016) claim that presence of depressive 
symptoms at discharge from medical units predicts the possibility of readmission or death.  The 
two participants who enrolled in the study and were lost to follow-up due to death had PHQ-9 
scores in the range of 20-27 (severe depression) at initial screening.  
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Feasibility of Depression Screening 
Li et al. (2009) reported that nearly 45% of patients with diabetes suffer from 
undiagnosed depression.  However, in the current study, 33.3% of population presented positive 
symptoms for depression.  Considering the number of patients excluded for reasons such as 
dementia and delirium and patients who declined to participate in the study, patients screened for 
depressive symptoms may not represent the actual population.  Also, the facility performs 
routine annual depression screening as part of primary care services.  Routine screening might be 
instrumental in reducing the number of patients with unidentified depressive symptoms. 
However, Shankman, Nadelson, McGowan, Sovari, and Vidovich (2012) reported the low 
sensitivity for annual screening in identifying depression among patients with Coronary Artery 
Disease.  This observation might be pertinent for patients with diabetes also.  After reviewing the 
negative outcomes in patients with medical illness and comorbid depression, IsHak and 
colleagues (2017) recommended screening for depressive symptoms in hospitalized patients with 
medical illnesses.   
In the current study, though participants were aware of their depressive symptoms, they 
did not report their symptoms to the providers.  However, when the participants received positive 
screens for depressive symptoms as part of the study, participants accepted treatment for their 
depressive symptoms.  The majority of the participants preferred management of depression 
from their medical provider and one of the participants reflected that he was not “crazy” to 
consult a mental health provider.  This comment may be an expression of the stigma associated 
with mental illness.  It is possible that patients who are reluctant to approach mental health 
providers for their depressive symptoms may receive management for their depressive symptoms 
if medical providers recognize these symptoms and offer management. 
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According to the current study, health care providers recognized the increased risk for 
comorbid depression in patients with diabetes and agreed with the benefits of depression 
screening during hospitalization.  Providers were confident in initiating the management for 
comorbid depression.  However, the providers acknowledged the benefits of collaboration with a 
mental health provider.  One of the providers who responded to the survey contemplated the 
possibility of “false positive screens” among hospitalized patients due to physical symptoms 
which may not indicate true depression.  However, evidence supports the feasibility and 
acceptability of depression screening in hospitalized patients using different screening tools 
including PHQ-9, the screening tool used in this study.  Sowden, Mastromauro, Januzzi, 
Fricchione, and Huffman, (2010) reported feasibility and acceptability of depression screening 
among hospitalized patients with cardiac conditions.  Wagner et al. (2017) supported the 
feasibility of screening for depressive symptoms in patients with cancer who were admitted to 
radiation oncology units.  Karamchandani et al. (2015) also favored the feasibility of the 
screening in patients who were hospitalized following a stroke. 
Limitations 
Outcomes of the current study concur with the existing evidence of unidentified 
depression in patients with diabetes and the effect of comorbid depression on patients’ health-
related quality of life and diabetes self-management.  However, the current study has several 
limitations, which include a very small sample size, a short duration of the study, and the 
absence of a control group.  Of the seven participants enrolled in the study, two participants died 
during the study period and lost follow-up.  Secondary to the short duration of the study, the 
effect of management of depressive symptoms on glycemic control was not measured.  The three 
screening tools used in the study are widely used and are capable of providing valuable data on 
depressive symptoms, quality of life and diabetes self-management.  Some of the questions in the 
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three questionnaires asked for same information though questions were worded differently.  It 
was noted that the participants provided slightly different responses to these questions within a 
single encounter.  It is likely that when these three surveys were administered in one session, the 
participants felt overwhelmed and answered some of the questions in haste.  Despite the 
limitations, this study addresses the effect of depression treatment on depressive symptoms, 
health-related quality of life, diabetes self-management, and health care utilization of adults with 
diabetes and comorbid depression. 
Implications for Practice 
The study confirms the presence of comorbid depression in patients with diabetes and 
initiates discussion on the feasibility of routine screening for depressive symptoms in patients 
with diabetes hospitalized with a medical illness.  The study offers opportunities for 
improvement in health care delivery by implementing routine screening and initiation of 
management for depressive symptoms in patients with diabetes during their hospitalization.  The 
three dimensions of the Triple Aim Framework proposed by Institute of Healthcare Improvement 
(IHI) for improved health care delivery are population focus, patient experience of care, and 
health care costs (Berwick, Nolan, & Whittington, 2013).  Comorbid depression act as a barrier 
in diabetes self-management leading to poor health-related quality of life and self-management 
outcomes.  Patients with diabetes and unmanaged depression report increased physical 
symptoms, have a higher risk of developing microvascular and macrovascular complications, 
poor quality of life, and increased utilization of emergency departments and inpatient services for 
ambulatory care sensitive conditions.  Identification of depressive symptoms in patients with 
diabetes and the initiation of management for the depressive symptoms satisfy the three 
dimensions of the Triple Aim Framework for improvement in health care quality. 
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According to the American Diabetes Association (2016), 25.9% of the older adults suffer 
from diabetes.  In the current study, the prevalence of diabetes was 35.8%.  Management of 
depressive symptoms in patients with diabetes benefits a large population.  As Knowles et al. 
(2015) described, collaborative management initiated by a medical provider is an opportunity for 
patients to overcome the stigma associated with depression and seek professional support for 
their depressive symptoms.  Improvement in health-related quality of life, self-management, and 
ability to manage their disease will improve patients’ experience and enhance patient’s 
satisfaction with health care services.  In addition to improvement in patient experience with care 
delivery, management of depressive symptoms may be cost effective.  According to the Agency 
for Healthcare Research and Quality's Healthcare Cost and Utilization Project, patients with 
diabetes and related complications have 20.3% re-admission rate within 30 days of discharge 
from a hospital (Elixhauser & Steiner, 2013).  In the Veterans Health Administration, healthcare 
spending for managing diabetes with comorbid depression accounts for the highest healthcare 
expenditure (Egede et al., 2015).  A decrease in healthcare spending evidenced in the study 
regarding reduction in preventable emergency department visits and hospitalizations supports the 
economic benefits of the routine screening and management of depressive symptoms.  
Outcomes of this study uphold the role of healthcare professionals in recognizing 
depressive symptoms in hospitalized patients with diabetes.  Any team members can administer a 
screening questionnaire for depressive symptoms with minimum training.  Nurses, healthcare 
providers, clinical social workers, case managers and professionals from those disciplines 
directly involved in patient care need ongoing education on the increased risk of depressive 
symptoms in patients with diabetes and the warning signs of depression.  The providers in this 
study appreciated the pocket cards with information from the Veterans Affairs/ Department of 
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Defense Clinical Practice Guidelines for Management of Depression.  Healthcare providers will 
benefit from ongoing education on depression management and opportunities for collaboration 
with inpatient mental health providers.  Improved communication between inpatient providers 
and outpatient providers may ensure appropriate post discharge follow-up. 
Plan to Sustain 
 The design of this program and utilizing the electronic medical record to communicate 
with healthcare providers was well received.  Plans to expand the program and working with the 
health care providers to make depression screening a part of every admission may take time, 
however, a worthwhile endeavor to continue to expand the program.  If this program becomes 
part of the entire Durham site, then it may be expanded to other sites in the state and the country.  
This feasibility study revealed barriers and achievements that will help in transitioning to other 
sites to potentially benefit a wider range of patients being served by the Veterans Administration.  
Conclusion 
Patients with diabetes have an increased risk of developing depressive symptoms.   
Depression management in patients with diabetes seems to improve their general health, daily 
activities and health-related quality of life and tends to reduce preventable emergency 
department visits and hospitalizations.  The current study supports the feasibility of screening for 
depressive symptoms in hospitalized patients with diabetes.  This study was conducted in a small 
group of participants over a short period.   Further research on long-term effects of depression 
management in patients with diabetes may provide future directions for care.  Also, future 
studies need to examine the effect of depression management in glycemic control of patients 
with diabetes and comorbid depression.
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APPENDIX A: PATIENT HEALTH QUESTIONNAIRE-2 (PHQ-2) 
Name:         Date: 
 
 
 
 
Over the past two weeks, how often have you been bothered by any of the following problems?  
 
 
 
Little interest or pleasure in doing things.  
0 = Not at all  
1 = Several days  
2 = More than half the days  
3 = Nearly every day  
 
 
Feeling down, depressed, or hopeless.  
0 = Not at all  
1 = Several days  
2 = More than half the days  
3 = Nearly every day  
 
 
 
Total point score: _________ 
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APPENDIX B: PATIENT HEALTH QUESTIONNAIRE-9 (PHQ-9) 
Over the last 2 weeks, how often have you been 
bothered by any of the following problems (Use 
“✔” to indicate your answer) 
Not at 
all 
Several 
days 
 
More 
than half 
the days 
 
Nearly 
every 
day 
 
1. Little interest or pleasure in doing things 0 1 2 3 
2. Feeling down, depressed, or hopeless  0 1 2 3 
3.Trouble falling or staying asleep, or sleeping too 
much  
0 1 2 3 
4.Feeling tired or having little energy  0 1 2 3 
5.Poor appetite or overeating  0 1 2 3 
6.Feeling bad about yourself — or that you are a 
failure or have let yourself or your family down  
0 1 2 3 
7. Trouble concentrating on things, such as reading 
the newspaper or watching television  
0 1 2 3 
8. Moving or speaking so slowly that other people 
could have noticed? Or the opposite — being so 
fidgety or restless that you have been moving 
around a lot more than usual  
0 1 2 3 
9.Thoughts that you would be better off dead or of 
hurting yourself in some way  
0 1 2 3 
 
Total  
 
0 + 
 
____ + 
 
____+ 
 
____ 
                                       
 Total Score 
 
 
10. If you checked off any problems, how difficult have these problems made it for you to do 
your work, take care of things at home, or get along with other people?  
Not difficult at all Somewhat difficult 
 
Very difficult 
 
Extremely difficult  
 
Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with 
an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or 
distribute.
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APPENDIX C: THE VETERANS RAND 12-ITEM HEALTH SURVEY (VR-12) 
The following questions ask for your views about your health—how you feel and 
how well you are able to do your usual activities. All kinds of people across the country are 
being asked these same questions. Their answers and yours will help to improve health care 
for everyone. There are no right or wrong answers; please choose the answer that best fits 
your life right now.  Answer each question by marking an ‘X’ next to the best response.  
 
Q1. In general, would you say your health is:  
 Excellent          Very good           Good           Fair         Poor  
Q2. The following questions are about activities you might do during a typical day. Does 
your health now limit you in these activities? If so, how much?  
 
a. Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling or      
playing golf?  
 Yes, limited a lot       Yes, limited a little      No, not limited at all  
b. Climbing several flights of stairs?  
 Yes, limited a lot       Yes, limited a little      No, not limited at all  
Q3. During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of your physical health?  
 
a. Accomplished less than you would like.  
 No, none of the time        Yes, a little of the time         Yes, some of the time  
 Yes, most of the time       Yes, all of the time  
b. Were limited in the kind of work or other activities.  
 No, none of the time     Yes, a little of the time    Yes, some of the time  
 Yes, most of the time   Yes, all of the time  
Q4. During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of any emotional problems (such as feeling depressed 
or anxious)? 
 
a. Accomplished less than you would like. 
 No, none of the time    Yes, a little of the time   Yes, some of the time 
 Yes, most of the time   Yes, all of the time  
b. Didn’t do work or other activities as carefully as usual. 
 No, none of the time         Yes, a little of the time      Yes, some of the time 
 Yes, most of the time        Yes, all of the time  
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Q5. During the past 4 weeks, how much did pain interfere with your normal work 
 (including both work outside the home and housework)? 
 Not at all         A little bit       Moderately      Quite a bit   Extremely 
These questions are about how you feel and how things have been with you during the past 4 
weeks. For each question, please give the one answer that comes closest to the way you have 
been feeling. 
 
Q6a. How much of the time during the past 4 weeks: Have you felt calm and peaceful? 
 All of the time        Most of the time             A good bit of the time 
 Some of the time    A little of the time          None of the time 
Q6b. How much of the time during the past 4 weeks: Did you have a lot of energy? 
 All of the time       Most of the time            A good bit of the time 
 Some of the time   A little of the time         None of the time 
Q6c. How much of the time during the past 4 weeks: Have you felt downhearted and blue? 
 All of the time        Most of the time             A good bit of the time 
 Some of the time     A little of the time          None of the time 
Q7. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting with friends, relatives, etc.)? 
 All of the time        Most of the time              Some of the time 
 A little of the time  None of the time 
Now, we’d like to ask you some questions about how your health may have changed. 
 
Q8. Compared to one year ago, how would you rate your physical health in general now? 
 Much better            Slightly better                About the same 
 Slightly worse         Much worse 
Q9. Compared to one year ago, how would you rate your emotional problems (such as 
feeling anxious, depressed or irritable) now? 
 Much better            Slightly better                About the same 
 Slightly worse         Much worse 
 
The Veterans RAND 12-item Health Survey was developed from the Veterans RAND 36 Item 
Health Survey which was developed and modified from the original RAND version of the 36-
item Health Survey version 1.0 (also known as the “MOS SF-36”) 
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APPENDIX D: STANFORD DIABETES QUESTIONNAIRE 
 
 
 
 
 
Stanford Patient Education Research Center  
                                                  Stanford University School of Medicine 
 
 
SAMPLE QUESTIONNAIRE 
 
DIABETES 
You may use all or parts of the questionnaire at no charge without permission  
Stanford Patient Education Research Center  
1000 Welch Road, Suite 204  
Palo Alto CA 94304  
(650) 723-7935 voice • (650) 725-9422 fax  
http://patienteducation.stanford.edu  
self-management@stanford.edu 
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Name:__________________________________________    Today's date: __________________ 
 
Address: _______________________________________________________________________ 
 
City, state, zip: __________________________________________________________________ 
 
Telephone: home (      ) - __                                               Date of birth: ______________________ 
 
Work (   ) – ______________________________________________________________________ 
 
Sex:  Female  Male  
Background  
1. Ethnic origin (check only one):  
 White not Hispanic                                                                 Asian or Pacific Islander  
 Black not Hispanic                                                                  Filipino  
 Hispanic                                                                                   American Indian/Alaskan Native  
 Other: __________________________  
 
 
 
2. Please circle the highest year of school completed:  
 
1 2 3 4 5 6 7 8  9 10 11 12     13 14 15 16 17 18 19      20 21 22 23+  
 
(primary)            (high school)       (college/university)             (graduate school)  
 
 
3. Are you currently (check only one):  
 
 married       separated        widowed       single      divorced  
 
 
4. Please indicate below which chronic condition(s) you have:  
 
 
 Diabetes type 2       Diabetes type 1      High cholesterol       High blood pressure  
 
 Heart disease Type of heart disease:  
 
 Lung disease Type of lung disease:  
 
 Other chronic condition Specify:  
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General Health 
 
1. In general, would you say your health is:  (Circle one)  
 
     Excellent...............................1  
 
     Very good..............................2  
 
      Good......................................3  
 
      Fair........................................4  
 
      Poor.......................................5 
 
Symptoms 
How much time during the past month...  
 
      None       A little      Some     A good       Most      All  
      of the       of the       of the     bit of the     of the    of the  
      time         time          time       time              time      time  
1. Were you discouraged by your  
health problems?.....................................            0             1             2           3                  4        5  
 
2. Were you fearful about your  
future health?.........................................             0              1             2           3                  4        5  
 
3. Was your health a worry in your life?....        0              1             2           3                  4        5  
 
4. Were you frustrated by your  
health problems?.....................................            0              1             2           3                  4        5  
 
 
 
5. We are interested in learning whether or not you are affected by fatigue. Please circle the number 
below that describes your fatigue in the past 2 weeks:  
   ___________________________________________ 
  0       1       2      3      4      5      6      7      8      9       10  
  No                                                                         Severe 
  Fatigue                                                                   Fatigue 
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6. We are interested in learning whether or not you are affected by pain. Please circle the number 
below that describes your pain in the past 2 weeks. 
                        ___________________________________________ 
  0       1       2      3      4      5      6      7      8      9       10  
  No                                                                         Severe 
  Pain                                                                        Pain 
 
 
7. We are interested in learning whether or not you are affected by shortness of breath. Please circle 
the number below that describes your shortness of breath in the past 2 weeks: 
 
                        ___________________________________________ 
  0       1       2      3      4      5      6      7      8      9       10  
  No                                                                         Severe 
      Shortness of       Shortness of 
                        Breath                                                                    Breath 
 
In the PAST WEEK, did you ever have any of the following symptoms?  
 
8. Increased thirst? ................................................................................ No  Yes  Don’t know  
9. Dry mouth?........................................................................................  No  Yes  Don’t know  
10. Decreased appetite? .......................................................................... No  Yes  Don’t know  
11. Nausea or vomiting? ......................................................................... No  Yes  Don’t know  
12. Abdominal pain?................................................................................ No  Yes  Don’t know  
13. Frequent urination at night? Do you have  
to get up to urinate 3 or more times a night?……….........................         No  Yes  Don’t know  
 
14. Severely high blood sugar  
(blood glucose readings of 300 mg or higher?) …….........................        No  Yes  Don’t know  
 
15. Morning headaches?.........................................................................    No  Yes  Don’t know  
16. Nightmares?....................................................................................... No  Yes  Don’t know  
17. Night sweats?..................................................................................... No  Yes  Don’t know  
18. Lightheadedness?............................................................................... No  Yes  Don’t know  
19. Shakiness or weakness?..................................................................... No  Yes  Don’t know  
20. Intense hunger?.................................................................................. No  Yes  Don’t know  
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21. Times when you passed out fainted or lost........................................ No  Yes  Don’t know  
consciousness, even for a short time? 
Daily Activities 
During the past 4 weeks, how much... (Circle one)  
       Not         Slightly      Moderately    Quite    Almost  
       at all                                                   a bit     totally  
1. Has your health interfered with  
your normal social activities with family,  
friends, neighbors or groups?..............................                0              1             2                3            4  
 
2. Has your health interfered with  
your hobbies or recreational activities?..............                 0               1             2                3           4  
 
3. Has your health interfered  
with your household chores?..............................                  0               1             2                3           4  
 
4. Has your health interfered with  
your errands and shopping?................................                  0                1             2               3           4 
 
Your Glucose Testing 
1. Do you have a machine to measure your blood sugar (glucose) level?       Yes      No  
 
2. On how many days in the last week did you test your blood sugar level? (If you were sick in the 
last week, think of the most recent 7 days when you were NOT sick)  ________ Days  
 
3. On days that you test your blood sugar, how many times do you test on average? _______ Times 
Physical Activities 
During the past week, even if it was not a typical week for you, how much total time (for the entire 
week) did you spend on each of the following? (Please circle one number for each question.)  
 
         Less than       30-60        1-3 hrs            More than  
      None      30 min/wk    min/wk      per week          3 hrs/wk  
1. Stretching or strengthening exercises  
(range of motion, using weights, etc.)................ 0              1                2              3                    4  
 
2. Walk for exercise............................................0               1                2              3                    4  
 
3. Swimming or aquatic exercise........................0               1                2              3                    4  
 
 
4. Bicycling (including stationary  
exercise bikes).....................................................0               1                2              3                    4  
 
 67 
5. Other aerobic exercise equipment  
(Stairmaster, rowing, skiing machine, etc.)........ 0               1                2              3                     4  
 
6. Other aerobic exercise  
Specify_________________________...............0               1                 2              3                    4  
 
Confidence About Doing Things 
For each of the following questions, please circle the number that corresponds with your 
confidence that you can do the tasks regularly at the present time.  
 
1. How confident do you feel that you can eat your 
meals every 4 to 5 hours every day, including 
breakfast every day? 
 
 
Not at all            |  |   |  |  |  |   |  |  |  |               Very 
confident           1  2 3 4 5 6 7 8 9 10       confident 
2.  2.  How confident do you feel that you can follow 
your diet when you have to prepare or share food 
with other people who do not have diabetes? 
 
 Not at all            |  |   |  |  |  |   |  |  |  |               Very 
confident           1  2 3 4 5 6 7 8 9 10       confident 
3. How confident do you feel that you can chose 
the appropriate foods to eat when you are hungry (for 
example, snacks)? 
 
Not at all            |  |   |  |  |  |   |  |  |  |               Very 
confident           1  2 3 4 5 6 7 8 9 10       confident 
 
                      
4. How confident do you feel that you can exercise 15 
to 30 minutes, 4 to 5 times a week?  
 
Not at all            |  |   |  |  |  |   |  |  |  |               Very 
confident           1  2 3 4 5 6 7 8 9 10       confident 
5. How confident do you feel that you can do 
something to prevent your blood sugar level from 
dropping when you exercise?  
 
Not at all            |  |   |  |  |  |   |  |  |  |               Very 
confident           1  2 3 4 5 6 7 8 9 10       confident 
6.How confident do you feel that you know what  
to    do when your blood sugar level goes higher or lower 
than it should be?  
 
Not at all            |  |   |  |  |  |   |  |  |  |               Very 
confident           1  2 3 4 5 6 7 8 9 10       confident 
7. How confident do you feel that you can judge 
when the changes in your illness mean you should 
visit the doctor?  
 
Not at all            |  |   |  |  |  |   |  |  |  |               Very 
confident           1  2 3 4 5 6 7 8 9 10       confident 
8. How confident do you feel that you can control 
your diabetes so that it does not interfere with the 
things you want to do?  
 
Not at all            |  |   |  |  |  |   |  |  |  |               Very 
confident           1  2 3 4 5 6 7 8 9 10       confident 
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Your Diet 
 
1. How many times last week did you eat breakfast when you got up? __      times last week  
 
2. This morning, did you eat any of the following foods for breakfast? (Please check all that apply)  
       milk (½ cup)  cheese  yogurt   eggs  meat, poultry, or fish  beans  
If you ate anything else, please write here:  
 
Medications 
1. In the past week did you take pills for diabetes?................... No  Yes  Don’t know  
 
Please specify the name(s) of the diabetes pills you took:  
 
 
2. In the past week did you get insulin injections?.................... No  Yes  Don’t know  
 
3. In the past week did you take pills for high blood pressure?   No  Yes  Don’t know  
 
Please specify the name(s) of the blood pressure pills you took:  
 
 
4. In the past week did you take pills for cholesterol?............... No  Yes  Don’t know  
 
Please specify the name(s) of the cholesterol pills you took:  
 
Medical Care 
 
1. When you visit your doctor, how often you do the following (please circle one number for each 
question):  
 Never 
Almost 
never 
Some 
times 
Fairly 
often 
Very 
often 
Always 
a. Prepare a list of questions for your doctor 
 
0 1 2 3 4 5 
b. Ask questions about the things you 
want to know and things you don’t 
understand about your treatment 
 
0 1 2 3 4 5 
c. Discuss any personal problems that 
may be related to your illness 
 
0 1 2 3 4 5 
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2. In the past 6 months, how many times did you visit a physician?  Do not include visits while in 
the hospital or the hospital emergency department........       __________ visits  
3. In the past 6 months, how many times did you go to a hospital emergency      
department?............................................................................__________ times  
4. In the past 6 months, how many TIMES were you hospitalized for one night or 
longer?.............................................................................................______ times  
a. How many total NIGHTS did you spend in the hospital in the  
past 6 months?.................................................................__________ nights  
b. Were any of these hospitalizations at a skilled nursing facility,  
convalescent hospital, or other minimum care facility?...................................... Yes  No  
5. When was the last time you had your eyes examined? (example: for glaucoma or any other 
problem).................................................. Month /Year  
6. How many times did the doctor or nurse examine your feet in the last 6 
months?....................................................................................._____________ times  
 
 
 
Thank you for your help!  
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APPENDIX E: SURVEY QUESTIONS FOR PARTICIPANTS AT THE END OF THE 
STUDY 
Thank you for your participation in this project. This is a voluntary survey to evaluate the 
feasibility of depression screening and management for patients when they are admitted to 
medical wards.  
1. What did you like about the study? 
2. Did you feel that you needed help regarding your depression? 
3. Did you receive medicine for your depression? 
4. Did you see a Psychologist for your depression? 
5. How do you feel since knowing that you have symptoms of depression? 
                Choose one - better/ worse/ same 
6. Did you like receiving telephone calls at 8 weeks and 12 weeks after discharge asking 
 you the questions about your symptoms, self- care, overall health, and hospital visits? 
7. Did you have any concerns for discussing depression symptoms with your provider 
 who helps you manage diabetes? 
8. What is your willingness to consult a mental health provider for depression symptoms?  
  a. Same as consulting the medical provider           
  b. I prefer medical provider helping me with my depression  
 c. I prefer a mental health specialist – Psychiatrist managing my depression  
  symptoms. 
9. In regards to your diabetes and depression management, how can we serve you better? 
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APPENDIX F: SURVEY QUESTIONS FOR PROVIDERS AT THE END OF THE 
STUDY 
Thank you for your participation in this project. This is a voluntary and anonymous survey to 
evaluate the feasibility of depression screening and management for comorbid depression in the 
medical setting.  
1. What did you like about the study process? 
 
2. What did you dislike about the study process? 
 
3. Do you consider patients with diabetes having higher risk for developing depression? 
 
4. Do you believe screening and management of co-morbid depression need to be  integrated into 
diabetes care? 
 
5. Did you like receiving an alert about your patients’ need for follow-up of depressive 
symptoms? 
 
6. Did you identify any difficulty in initiating depression management? If yes, mention it  here? 
 
7. How confident are you in initiating management of co-morbid depression in patients  with 
diabetes? 
 
8. What would you suggest to improve the process of screening and starting management  for co-
morbid depression during their hospitalization? 
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APPENDIX G: CONSENT FORM 
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APPENDIX H: AUTHORIZATION FOR THE USE AND RELEASE OF 
INDIVIDUALLY IDENTIFIABLE HEALTH INFORMATION 
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APPENDIX I: PROVIDER POCKET CARD 
VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder 
Nine Symptom Checklist (PHQ-9) 
                                                                                                                                         More         Nearly 
Over the last 2 weeks, how often have you been                   Not at       Several    than half    
every 
bothered by any of the following?                                        all             days         the days         a Little interest or pleasure in doing things? 0 1 2 3 
b Feeling down, depressed, or hopeless? 0 1 2 3 
c Trouble falling or staying asleep, or sleeping too much? 0 1 2 3 
d Feeling tired or having little energy? 0 1 2 3 
e Poor appetite or overeating? 0 1 2 3 
f Feeling bad about yourself—or that you are a failure or 
have let yourself or your family down? 
0 1 2 3 
g Trouble concentrating on things, such as reading 
the newspaper or watching television? 
0 1 2 3 
h Moving or speaking so slowly that other people could 
have noticed? Or the opposite—being so fidgety or 
restless that you have been moving around a lot more 
than usual? 
0 1 2 3 
i Thoughts that you would be better off dead or of 
hurting yourself in some way? 
0 1 2 3 
For office coding: Total Score =          +           +           + 
  
Antidepressant Dosing and Monitoring 
Class Agent Initial Dose Titration Max 
dose/day 
Initial dose/ Guidance Specific populations 
Geriatrics Renal Hepatic Pregnancy 
FDA 
Category 
 
 
 
 
 
 
 
 
 
 
SSRIs 
Citalopram 20 mg once 
a day 
20 mg 
weekly 
40 mg; 20 
mg geriatric 
10-20 mg 
once a day 
Avoid: CrCl 
<20 ml/min 
↓ dose C 
Escitalopram 10 mg once 
a day 
10 mg 
weekly 
20 mg 5-10 mg once 
a day 
Avoid: CrCl 
<20 ml/min 
10 mg once 
a day 
C 
Fluoxetine 20 mg once 
a day 
20 mg 
every 2 
weeks 
80 mg 10 mg once a 
day 
↓ dose 
and/or 
↓ frequency 
↓ dose 50% C 
Fluoxetine 
weekly 
90 mg once 
a week 
N/A 90 mg 90 mg once a 
week 
No change Avoid C 
Paroxetine 20 mg once 
a day 
20 mg 
weekly 
50 mg 10 mg once a 
day 
10 mg once a 
day 
10 mg once 
a day 
D 
Paroxetine 
CR 
25 mg once 
a day 
12.5 mg 
weekly 
62.5 mg; 50 
mg geriatric 
12.5 mg; 
once a day 
12.5 mg 
once a day 
12.5 mg 
once a day 
D 
Sertraline 50 mg once 
a day 
50 mg 
weekly 
200 mg 25 mg once a 
day 
25 mg once a 
day 
↓ dose C 
Vilazodone 10 mg once 
a day 
10 mg 
weekly 
20-40 mg 5 mg No change No change C 
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VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder 
Antidepressant Dosing and Monitoring 
Class Agent Initial 
Dose 
Titration Max 
dose/day 
Initial dose/ Guidance Specific populations 
Geriatric Renal Hepatic Pregna
nacy 
SNRIs 
Duloxetine 
20-30 mg 
twice a 
day 
20-30 mg 
weekly 
60 mg 
20 mg 
once or 
twice a 
day 
Avoid if 
CrCl 
<30 
ml/min 
Avoid C 
Venlafaxine IR 
37.5 mg 
twice a 
day 
75 mg 
weekly 
225-375 
mg 
25mg 
once or 
twice a 
day 
↓dose 
based 
on CrCl 
↓ dose 50% C 
Venlafaxine 
XR 
75 mg 
once a 
day 
75 mg 
weekly 
225 mg 
37.5-75 
mg once 
a day 
↓dose 
based 
on CrCl 
↓ dose 50% C 
Levomilnacipr
an 
20 mg 
once a 
day 
20-40 mg 
every 2 
days 
120 mg 
Refer to 
adult 
dosing 
Max 
doses 
less if 
CrCl<60
ml/min 
No change C 
Desvenlafaxine 
50 mg 
once a 
day 
Unnecess
ary 
100 mg; 
Consider 
CrCl 
CrCl 
<30, 
25mg 
daily 
No change C 
5-HT3 
receptor 
antagonist 
Vortioxetine 
10 mg 
once a 
day 
10 mg 
once 
daily 
5-20mg 
5-20 mg 
once a 
day 
No 
change 
Severe: not 
recommen
ded 
 
NDRIs 
Bupropion IR 
100 mg 
twice a 
day 
100 mg 
weekly 
450 mg 
37.5mg 
twice a 
day 
Has not 
been 
studied 
Severe: 
75 mg/day 
 
Bupropion SR 
150 mg 
once a 
day 
150 mg 
weekly 
200 mg 
twice 
daily 
100 mg 
once a 
day 
100 mg 
once a day 
or 150 mg 
every other 
day; 
C 
Bupropion XR 
150 mg 
once a 
day 
150 mg 
weekly 
450 mg 
150 mg 
once a 
day 
C 
5-HT2 
receptor 
antagonist 
Trazodone 
50 mg 
three 
times a 
day 
50 mg 
weekly 
600 mg 
25-50 mg 
bedtime 
 Unknown C 
Nefazodone 
100 mg 
twice a 
day 
100 mg 
weekly 
600 mg 
50 mg 
twice a 
day 
No 
change 
Avoid C 
Noradrene
rgic 
antagonist 
Mirtazapine 
15 mg 
daily at 
bedtime 
15 mg 
weekly 
45 mg 
7.5 mg at 
bedtime 
Caution 
in renal 
impairm
ent 
Cl ↓ 30% C 
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Antidepressant Dosing and Monitoring 
Class Agent Initial 
Dose 
Titration Max 
dose/day 
Initial dose/ Guidance Specific populations 
Geriatric Renal Hepatic Pregnancy 
risk 
TCAs Amitript
yline 
25-50 mg 
daily 
Weekly 300 mg 
10–25 
mg 
No 
change 
 
Lower dose 
and slower 
titration 
recommend
ed 
C 
Imiprami
ne 
25 mg 1- 4 
times/day 
Weekly 300 mg 
10-25 
mg at 
Un 
classified 
 
 
Nortripty
line 
25 mg 3-4 
times/day 
Weekly 150 mg 
30-50 
mg/day 
Desipra
mine 
25-50 mg 
once daily 
or in 
divided 
doses 
Weekly 
300 mg; 
150 mg 
geriatric 
10-25 
mg 
once a 
day 
Doxepin 
25-50 mg 
daily at 
bedtime or 
twice a day 
Weekly 300 mg 
Low 
dose, 
once 
daily 
 
MAOIs 
Isocarbo
xazid 
10 mg 
twice a day 
10 mg/day 
every 2-4 days 
to 40 mg/day. 
After first 
week, may 
increase by up 
to 20 mg/week 
to a Max 60 
mg/day. 
60 mg 
10 mg 
twice a 
day 
Avoid in 
any renal 
impairme
nt. 
Contraindic
ated in 
history of 
liver 
disease or 
abnormal 
LFTs 
C 
Phenelzi
ne 
15 mg 3 
times a day 
Increase 
rapidly, based 
on patient 
tolerance, to 
60-90 mg/day 
90 mg; 
60 mg 
geriatric 
7.5 mg 
once a 
day 
Avoid if 
severe 
Avoid 
Undeterm
ined 
Selegilin
e patch 
6 mg/24 
hours 
3 mg/24 hours 
every 2 weeks 
12 mg/24 
hours 
6 g/24 
hours 
Use in 
CrCl <15 
ml/min - 
not 
studied 
Mild to 
mod: no 
adjustment 
Severe: - 
not studied 
 
not studied 
C 
Tranylcy
promine 
10 mg 
twice/day 
10 mg weekly 60 mg 
10 mg 
twice a 
day 
No 
change 
Avoid C 
Abbreviations: 5-HT = serotonin, BID = twice a day, CrCl = creatinine clearance, CR = controlled release, IR = immediate 
release, LFT = liver function test, MAOI = monoamine oxidase inhibitor, mg = milligram, min = minute, ml = milliliter, N/A= 
not applicable, NDRI= norepinephrine and dopamine reuptake inhibitor, QD = once a day, QHS = once before bedtime, QID = 
four times a day, QOD = every other day, SNRI = serotonin norepinephrine reuptake inhibitor, SR = sustained-release, SSRI = 
selective serotonin reuptake inhibitor, TCA = tricyclic antidepressant, TDM = therapeutic drug monitoring, XR = extended-
release
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Antidepressant Adverse Event Profiles 
Drug class/ 
drug 
Amine 
Update 
Antic
-
holine
rgic 
activit
y 
Seda
tion 
(H1 
Acti
vity 
Orthos
tatic 
Hypote
-nsion 
(alpha 
1act) 
Car
diac 
Con
duc
tion 
GI 
effec
ts 
Weight 
gain 
Comments 
5HT NE 
SSRIs +++ 0/+ 0/++ 0/ + 0 0/+ +++ 0/+ 
Sexual dysfunction common; 
Citalopram and escitalopram 
dose-related conduction effects 
  Paroxetine most anticholinergic; 
avoid in elderly ;    Paroxetine 
and fluoxetine CYP2D6 and 
CYP2B6 inhibitors ;    
Vilazodone CYP2C8 2C1 and 
2D6 inhibitor 
SNRIs 
++/+
++ 
++/+
++ 
0/+ 0/+ 0/++ 0/+ 
++/+
++ 
0/+ 
Sexual dysfunction common 
Venlafaxine NE activity dose- 
related;   Desvenlafaxine active 
metabolite of venlafaxine 
Bupropion 0/+ 0/+ 0 0 0 0 ++ 0 
Risk of seizures is dose- related; 
avoid if seizure history, bulimia 
or eating disorder;     CYP2D6 
inhibitor 
Trazodone 
Nefazodone 
+++ 0/+ 0 +++ 0 0/+ ++ 0/+ 
Very sedating;   Nefazodone 
associated with a higher risk of 
hepatotoxicity ;      Nefazodone 
CYP3A4 inhibitor 
Mirtazapine 0/+ 0/+ 0 +++ 0/+ 0 0/+ +++ 
Doses >15 mg less sedating.  
May stimulate appetite 
Vortoxetine +++ ++ 0 0 0 0 +++ 0 
 
TCAs 
 
+/++
+ 
+/++
+ 
+/+++ 
0/++
+ 
+/+++ 
++/
+++ 
0/+ 0/++ 
Desipramine and nortriptyline 
more tolerable; least sedating, 
anticholinergic and orthostatic 
hypotension 
     Therapeutic blood 
concentrations established for 
desipramine, imipramine, and 
nortriptyline 
MAOI s 0 0 0 0/+ 0/+ 0 0/+ 0/+ 
Requires a low tyramine diet 
except selegiline patch     
Contraindicated with other 
antidepressants 
sympathomimetics and 
Key: +++ = strong effect, ++ = moderate effect, + = minimal effect, 0 = no effect 
Abbreviations: MAOI = monoamine oxidase inhibitor, SNRI = serotonin norepinephrine reuptake inhibitor, SSRI = Selective 
serotonin reuptake inhibitor, TCA = tricyclic antidepressant 
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APPENDIX J: INSTITUTIONAL REVIEW BOARD APPROVAL FROM VETERAN’S 
AFFAIRS MEDICAL CENTER DURHAM  
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APPENDIX K: INSTITUTIONAL REVIEW BOARD AMENDMENT APPROVAL 
FROM VETERANS AFFAIRS MEDICAL CENTER DURHAM 
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APPENDIX L: INSTITUTIONAL REVIEW BOARD APPROVAL FROM UNIVERSITY 
OF NORTH CAROLINA CHAPEL HILL 
 
 
 
To: Letha Joseph 
School of Nursing 
 
From: Non-Biomedical IRB 
 
Approval Date: 7/26/2016 
Expiration Date of Approval: 7/25/2017 
RE: Notice of IRB Approval by Expedited Review (under 45 CFR 46.110) 
Submission Type: Initial 
Expedited Category: 7.Surveys/interviews/focus groups 
Study #: 16-0886 
 
Study Title: Depression in Veterans with Diabetes 
 
This submission has been approved by the IRB for the period indicated. It has been 
determined that the risk involved in this research is no more than minimal. 
 
Study Description: 
Purpose: The purpose of this Doctorate in Nursing Practice scholarly project is to 
explore the feasibility of depression screening and follow-up for veterans admitted to Durham 
VA Medical Center with diabetes and to evaluate the effect of depression management in 
depressive symptoms, health related quality of life, self- reported diabetes self- management and 
all-cause 30-day readmission rates of veterans with diabetes. 
 
Participants: Participants of this project will be a convenience sample of 50 veterans 
admitted to hospitalist medical team during the study period with a primary diagnosis of diabetes 
and has glycated hemoglobin of seven or higher 
 
 
OFFICE OF HUMAN RESEARCH ETHICS 
720 Martin Luther King, Jr. Blvd.  
Bldg. 385, 2nd Floor 
CB #7097 
Chapel Hill, NC 27599-7097  
(919) 966-3113 
Web site: ohre.unc.edu 
Federalwide Assurance (FWA) #4801 
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Procedures (methods): After identification of potential participants using the above 
inclusion criteria, the DNP student will secure informed consent from the participants and 
administer Patient Health Questionnaire – 2 (PHQ-2). Patients screen negative using the PHQ-2 
will be excluded from the project. Those patients scoring ≥ 3 for the PHQ-2 will receive 
additional screening using the nine item questionnaire PHQ-9 to quantify the severity of 
depressive symptoms.  DNP student will discuss the results of the screening with the patient. 
Additionally their Health Related Quality of Life (HRQoL) will be evaluated using the Veterans 
RAND 12-item health survey (VR-12) diabetes self-management using Stanford Diabetes 
Questionnaire. The DNP student will update the inpatient provider about presence and severity 
of depression symptoms using the computerized patient record system (CPRS), the electronic 
health records used in the facility. 
 
The inpatient provider will discuss depression management options with the participant 
and will make depression management plans honoring the patient’s choice. Depending on the 
severity of depression symptoms and patient’s acceptance, the hospitalist provider will make 
referrals to a clinical psychologist, prescribe antidepressants or refer to an inpatient psychiatrist.  
Upon discharge from the inpatient unit, patient will receive a schedule for a follow-up 
appointment with their primary care provider in 30 days. The primary care provider will continue 
to follow the patients’ severity of depression and continued management during routine 
outpatient visits. 
 
At eight weeks and twelve weeks following discharge from the hospital, the DNP 
student will contact the participant via telephone. During this telephone follow-up, the 
participant will be screened for depression symptoms, diabetes self- management and HRQoL 
using PHQ-9, VR-12 and Stanford Diabetes Questionnaires. 
 
Regulatory and other findings: 
This approval includes a limited waiver of HIPAA authorization to identify potential 
subjects for recruitment into this research study, as allowed under 45 CFR 164.512. This 
temporary waiver provides access to protected health information (PHI) to confirm eligibility 
and facilitate initial contact, after which consent and HIPAA authorization will be sought when 
applicable. Access and use is limited to the minimum amount of PHI necessary to review 
eligibility criteria and to contact potential subjects. 
 
Investigator’s Responsibilities: 
Federal regulations require that all research be reviewed at least annually. It is the 
Principal Investigator’s responsibility to submit for renewal and obtain approval before the 
expiration date. You may not continue any research activity beyond the expiration date without 
IRB approval. Failure to receive approval for continuation before the expiration date will result 
in automatic termination of the approval for this study on the expiration date. 
 
Your approved consent forms and other documents are available online at 
http://apps.research.unc.edu/irb/index.cfm?event=home.dashboard.irbStudyManagement&irb_id
=16-0886. 
 
You are required to obtain IRB approval for any changes to any aspect of this study 
before they can be implemented. Any unanticipated problem involving risks to subjects or others 
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(including adverse events reportable under UNC-Chapel Hill policy) should be reported to the 
IRB using the web portal at http://irbis.unc.edu. 
 
Please be aware that additional approvals may still be required from other relevant 
authorities or "gatekeepers" (e.g., school principals, facility directors, custodians of records). 
 
The current data security level determination is Level III. Any changes in the data 
security level need to be discussed with the relevant IT official. If data security level II and III, 
consult with your IT official to develop a data security plan. Data security is ultimately the 
responsibility of the Principal Investigator. 
 
This study was reviewed in accordance with federal regulations governing human 
subjects research, including those found at 45 CFR 46 (Common Rule), 45 CFR 164 (HIPAA), 
21 CFR 50 & 56 (FDA), and 40 CFR 26 (EPA), where applicable. 
 
CC: 
Diane Berry, School of Nursing 
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APPENDIX M: INSTITUTIONAL REVIEW BOARD AMENDMENT APPROVAL 
FROM UNIVERSITY OF NORTH CAROLINA CHAPEL HILL 
 
 
 
 
 
 
 
 
To: Letha Joseph 
School of Nursing 
From: Non-Biomedical IRB 
 
Approval Date: 11/28/2016 
Expiration Date of Approval: 7/25/2017 
RE: Notice of IRB Approval by Expedited Review (under 45 CFR 46.110) 
Submission Type: Modification 
Expedited Category: 7.Surveys/interviews/focus groups, Minor Change to Previously Approved 
Research 
Study #: 16-0886 
 
Study Title: Depression in Veterans with Diabetes 
This submission has been approved by the IRB for the period indicated. It has been 
determined that the risk involved in this modification is no more than minimal.  Unless 
otherwise noted, regulatory and other findings made previously for this study continue to be 
applicable. 
Submission Description: 
Extension of study period from 31st December 2016 to 28th February 2017.  Patient enrollment 
will extend until December 31st and newly enrolled participants will be enrolled in the study till 
28th February 2017 or until 12 weeks of discharge from the hospital, whichever comes first. 
Amendment is requested to reflect these changes in the consent form ( pages 1 and 2). 
Investigator’s Responsibilities: 
If applicable, your approved consent forms and other documents are available online at 
http://apps.research.unc.edu/irb/index.cfm?event=home.dashboard.irbStudyManagement&irb_id
=16-0886. 
The current data security level determination is Level III. Any changes in the data security level 
need to be discussed with the relevant IT official. If data security level II and III, consult with 
your IT official to develop a data security plan. Data security is ultimately the responsibility of 
the Principal Investigator. 
This study was reviewed in accordance with federal regulations governing human subjects 
research, including those found at 45 CFR 46 (Common Rule), 45 CFR 164 (HIPAA), 21 CFR 
50 & 56 (FDA), and 40 CFR 26 (EPA), where applicable. 
 
CC: 
Diane Berry, School of Nursing 
 
OFFICE OF HUMAN RESEARCH ETHICS 
720 Martin Luther King, Jr. Blvd.  
Bldg. 385, 2nd Floor 
CB #7097 
Chapel Hill, NC 27599-7097  
(919) 966-3113 
Web site: ohre.unc.edu 
Federalwide Assurance (FWA) #4801 
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APPENDIX N: PERMISSION TO USE VR-12 QUESTIONNAIRE 
 
B   O   S   T   O   N       U   N   I   V   E   R   S   I   T   Y       M   E   D   I   C   A   L        C   E   N   T   E   R 
 
S C H O O L  O F  M E D I C I N E  •  S C H O O L  O F  P U B L I C  H E A L T H  •  G O L D M A N  S C H O O L  O F  D E N T A L  M E D I C I N E  •  B O S T O N  M E D I C A L  C E N T E R  
 
 
Boston University  
School of 
Public Health 
 
Department of Health Policy & 
Management 
                       715 Albany Street, T3W 
                       Boston, Massachusetts 
                       02118-2526 
                       Tel: 617 638-5042 
                       Fax: 617 638-5374 
June 29 2016  
Letha M Joseph, MSN, RN, AGPCNP-BC 
DNP Student, UNC Chapel Hill, NC 
Letha.joseph@va.gov  
Dear Letha, 
I am in receipt of your letter and description of the project. This letter will serve to 
give you permission to use the Veterans RAND 12-item Health Survey (VR-12) and/or 
the Veterans RAND 36 Item Health Survey (VR-36) subject to the conditions as 
specified in the memorandum attached to this e-mail. This includes the appropriate 
attribution given for the VR-12/VR-36 as noted below. 
The VR-36 and VR-12 are in the public domain and there is no cost for their use. 
The VA Office of Quality and Performance have previously used the RAND 12-item 
Health Survey (VR-12) as part of the SHEP National Survey in the VA and earlier the 
VR-36 in the 1999 Large Health Survey of Veterans.  CMS has also endorsed the use 
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of the VR-12 in their Health Outcome Survey to assess the outcomes of the Medicare 
Advantage Program on a national basis.  The VR-36 and VR-12 were developed with 
the use of federal funds and were modifications from the MOS SF-36 version. You are 
free to use the VR-12/VR-36 assessment tool, for the specific purpose/study described 
in your request. Any other use of the VR-36 or VR-12 will require a separate request for 
approval.  
In any use of the VR-12 the user needs to provide the correct and complete 
attribution with references as follows, “the Veterans RAND 12-item Health Survey was 
developed from the Veterans RAND 36 Item Health Survey which was developed and 
modified from the original RAND version of the 36-item Health Survey version 1.0 (also 
known as the “MOS SF-36”). For the VR-36 the attribution needs to read that this was 
developed from the MOS SF-36. In addition to note that the user will comply with the 
uses of the Rand 36-Item Health Survey given at the Web Site: 
http://www.rand.org/health/surveys/sf36item/permission.html.   
We have also attached the package of documentation, including the 
questionnaire, 'scoring guide' and 'algorithms for scoring' including imputation of missing 
values. If the imputation approaches reflected in these algorithms are used proper credit 
needs to be given by citing the document on scoring and imputation contained in this 
package (Spiro A, Rogers W, Qian S and Kazis L.  Imputing Physical and Mental 
Summary Scores (PCS and MCS) for the Veterans SF-12 Health Survey in the Context 
of Missing Data, Sept. 2004, Report submitted to CMS.)  A reference list of publications 
is also included.  
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Good luck with your work and we will keep you posted of any further updates and 
releases related to the VR-36 or the VR-12. 
  
Sincerely, 
  
  
 
Lewis E. Kazis, Sc.D. 
Professor and Director 
Center for the Assessment of Pharmaceutical Practices 
Department of Health Policy and Management 
Boston University School of Public Health 
And 
Chief, Pharmaco-Outcomes and Epidemiology Section 
Center for Health Quality, Outcomes and Economic Research (CHQOER) 
Veterans Administration Medical Center, Bedford, MA. 
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